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Kaitlin Madeline Sullivan, MS 
University of Pittsburgh, 2019 
Psychiatric genetic counseling (PGC) is a growing specialty. With discoveries of new 
treatments, improved risk calculations, elucidation of genes associated with psychiatric disorders, 
and rising public interest in mental health, the occasion for genetic counselors to address 
psychiatric genetics in sessions will likely become more common. Several papers have addressed 
the utility and efficacy of PGC. Additionally, studies have shown that experience with mental 
illness, training for psychiatric genetic counseling, stigma towards individuals with mental illness, 
and concerns about communicating complex information all affect genetic counselors’ attitudes 
and practices regarding psychiatric genetics. It is important to determine whether and how 
nonpsychiatric genetic counselors employ it to determine what information would most enhance 
practices and how best to disseminate that information.  
This study looked at how exposure, training, and resources influence genetic counselors’ 
practices and confidence by surveying 108 members of the National Society of Genetic Counselors 
about their current practices, what factors influence those practices, and what resources or 
information would benefit patient care. The majority of counselors indicated they have never seen 
a patient whose primary indication was a psychiatric condition (n=68), referred a patient to a 
psychiatric genetic counselor (n=88), disclosed secondary findings related to a psychiatric 
condition (n=83), or ordered genetic testing primarily for a psychiatric disorder (n=87).  
  Abstract
 v 
These findings indicate that although dedicated clinics are being developed and interest is 
rising, PGC is not used by the majority of genetic counselors. Nevertheless, recent graduates of 
genetic counseling programs were more likely to have attended a training program that addressed 
psychiatric genetics and were more confident in their knowledge of psychiatric genetics, indicating 
that changes in the field of genetic counseling and individual experience in the field may affect 
familiarity, confidence, and practice. This study demonstrates that development of training 
programs, resources, and educational opportunities may increase adoption of psychiatric genetic 
counseling practices, potentially improving care of patients with mental illnesses. Caring for those 
with mental illness is an important focus in public health, and development of policies, guidelines, 
and provider resources can be informed by this study’s assessment of factors involved in PGC 
decisions.  
 vi 
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1.0 Introduction 
Psychiatric genetic counseling involves evaluation of patients’ psychiatric histories, 
recognition of patterns or trends of psychiatric disorders or other neurodevelopmental disorders in 
family histories, assessment of risks, and communication of risks, causes of mental illness, and 
potential genetic testing or management, as well as discussion of patients’ fears, guilt, blame, and 
other emotions surrounding psychiatric disorders.1,2 Understanding the complex etiologies of 
mental illness can reduce stigma and shame, help individuals feel more in control of their mental 
health, and potentially influence treatments and therapies.3,4 
Over 46.6 million people over 18 in the United States, or 18.9% of the population, had a 
mental illness in 2017.5 This is a significant increase from 18.1% in 2014, 17.8% in 2011, and 
17.7% in 2008.6,7 This increase is reflected in rising disability payments, with average monthly 
benefits for all disabled beneficiaries with mental disorders increasing from $6473 in 2010 to 
$7228 in 2017.6,7 The large affected proportion of society and the financial burden of mental 
healthcare have increased public interest and funding for psychiatric research, allowing for 
development of new treatments, identification of risk factors, and better understanding of brain 
development and function.8 Genetic associations and links between psychiatric conditions, 
developmental and intellectual disabilities, and physical symptoms contribute to development of 
medications and treatments, as well as more accurate risk conceptualizations. Early hypotheses of 
candidate genes based on targets of psychiatric medications were later tested with linkage analysis 
studies and genome-wide association studies (GWAS), which then led to identification of more 
loci and genes associated with psychiatric disorders.9,10,11,12 
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Public health campaigns have improved public awareness and acceptance of mental 
illnesses, which, in combination with revised Diagnostic and Statistical Manual for Mental 
Disorders (DSM) criteria and other factors, have contributed to higher numbers of referrals to 
mental health professionals and prescriptions of psychiatric medications.13 Demand for care of 
individuals with psychiatric disorders and for genetic counseling services are both growing; 
therefore it can be expected that psychiatric genetic counseling will be increasingly called for.7,14,15 
As knowledge improves of the mechanisms of psychiatric illness pathophysiology, identification 
of genes, loci, and epigenetics involved in mental health, clearer determinations of heritability and 
recurrence risks, and applications of pharmacogenomics, the role of genetic counselors in 
psychiatry is growing and changing. 
Dedicated psychiatric genetic counseling clinics have developed strategies for working 
with patients and families with histories of mental illness, and studies have revealed positive 
outcomes of these clinics.4,6,7,16 Genetic counselors in other specialties also see patients with 
personal or family histories of psychiatric conditions but have received varying levels of education 
and training to provide psychiatric genetic counseling.17 The field of psychiatric genetics has 
changed greatly from early descriptions of psychiatric disorders in families to recent identification 
of specific genes increasing risk of mental health issues, and communicating new findings and 
conceptualizations may be beneficial to genetic counselors’ practice and patients’ care. 
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1.1 Specific Aims 
• Aim 1 – Establish whether and how genetic counselors are currently incorporating 
knowledge of psychiatric disorders into their counseling sessions.  
• Aim 2 – Determine what information about psychiatric disorders is most important and 
most desired by genetic counselors.  
• Aim 3 – Propose methods to disperse this information and increase genetic counselors’ 
knowledge and comfort with discussing psychiatric disorders.  
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2.0 Literature Review 
2.1 History of Psychiatric Genetics 
Psychiatry has been studied for centuries, from early observations by ancient cultures to 
the creation of the American Psychiatric Association in 1844, and much of these studies have 
focused on the origins and causes of mental illness.18 Early anecdotal recognition of psychiatric 
disorders clustering in families directed later research towards familial explanations of mental 
illness. The German Research Institute for Psychiatry was founded in 1917 with a “Genealogic-
Demographic Department,” approximately 50 years after Gregor Mendel’s work on inheritance.19 
Since then, numerous research programs and clinics have been developed.20,21 In 1983, a clinical 
and research team was developed by Russell Schachar to study attention-deficit disorder (ADHD) 
and genetics.20 Dr. Schachar also helped develop a joint clinical and research program involving 
psychiatric genetics at The Hospital for Sick Children in Toronto, Canada.20 Since 2006, 
Washington University School of Medicine in St. Louis has had a “First Contact Assessment 
Service” designed to provide evaluations of individuals with psychiatric conditions to their 
psychiatrists and other providers.21 Their Psychiatric Genetics Assessment evaluates those with 
psychiatric disorders related to genetic conditions.2121  
Many universities and researchers are involved in the Psychiatric Genetics Consortium, 
formed in 2007 to use open-source data to investigate the genetic basis of psychiatric disorders, 
possible therapeutic targets for psychiatric drugs, improve diagnoses, and other initiatives.22 The 
elucidation of “nature” vs. “nurture” has long been a topic of debate, with recent consensus that 
both play a role.23,24,25 Determining the specific roles of genetics, environment, experiences, and 
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other factors in the development of psychiatric disorders has been one of the focal points of recent 
research, as understanding the pathophysiology and origination of psychiatric conditions may lead 
to improved treatments and therapies.19  
2.1.1  Heritability Studies 
The heritability of psychiatric disorders has long been studied, and the heritability of 
schizophrenia was one of the first focuses, followed next by depression, bipolar disorder, autism 
spectrum disorder (ASD), anxiety disorders, and other psychiatric conditions.9 As early as 1911, 
family studies on psychiatric disorders were performed.26 Family, twin, and adoption studies 
helped to define characteristics of the heritable phenotypes, estimate heritability, and investigate 
contributions and interactions of genetic and environmental factors.27 In 1946, Franz Kallmann 
performed a landmark twin study including 691 twin families, including monozygotic and 
dizygotic twins, full siblings, half-siblings, step-siblings, parents, and twins’ marriage partners to 
elucidate the environmental and genetic contributions to development of schizophrenia.28 Given 
that the concordance rates Kallmann found were higher than those in other family studies of 
schizophrenia, his investigations of “the genetic theory of schizophrenia” contributed to growth of 
the field.28  Sullivan et al. used 12 twin studies of schizophrenia published between 1941 and 1999 
in Europe and the United States to estimate the heritability of schizophrenia at 73-90%.29 These 
studies recruited subjects systematically, but typical exclusion data was relaxed to allow for 
inclusion of older studies performed before blinding of diagnosis and zygosity and systematic data 
collection and diagnosis were the norm. Nevertheless, comparison of “inferior studies” with 
“methodologically superior” studies revealed similar estimations of genetic and environmental 
effects.29  
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Meta-analysis of five family studies and six twin studies on major depressive disorder 
(MDD) and qualitative analysis of three adoption studies estimated heritability of depression to be 
approximately 31-42%.27 These studies, published between 1980 and 1999 and performed 
primarily in the United States, as well as Europe and Australia, were selected for systematic 
recruitment, distinction between unipolar major depressive disorder and bipolar depression, 
blinded diagnoses, and direct collection of diagnostic data.27 The subjects were recruited from 
clinical settings, the general population, and screened medical patients. 
Johansson et al. used data from the Swedish Twin Register and the National Patient 
Register of twins born in Sweden between 1940 and 2005 to estimate heritability of bipolar 
disorder (BPD) at approximately 60%.30 The authors utilized the liability-threshold model to 
evaluate additive genetic and environmental effects and accounted for the fact that subjects may 
still be at risk to develop or be diagnosed with BPD by the end of the study’s follow-ups, because 
due to the uncertainty of whether a depressive episode will eventually develop into bipolar 
disorder, there can be a lag before individuals are diagnosed with BPD.30  
Tick et al. reviewed all twin studies of ASD at time of publication and analyzed seven twin 
studies that met systematic recruitment criterion. 31 Six of these studies were performed in Europe 
and one in Japan, all published between 1985 and 2015. The authors analyzed concordance 
between monozygotic and dizygotic twins, calculating the heritability of ASDs to be 64-91%.31  
The heritability of generalized anxiety disorder was estimated at 32% by Hettema et al. in 
2001, who performed a meta-analysis of five family studies and three twin studies of generalized 
anxiety disorder as well as panic disorder, obsessive-compulsive disorder, and phobias.32 The 
authors included studies using adults, systematic ascertainment, direct interviews, and blindness 
of affected status.32 The highly heritable nature of these conditions explains why genetic 
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counselors may see patients who report multiple family members with intellectual, behavioral, and 
psychiatric disorders. 
2.1.2  Candidate Genes and Loci 
Another significant area of research in the field of psychiatric genetics has been the 
identification of candidate genes associated with psychiatric illnesses. Candidate genes were 
largely hypothesized based on targets of antipsychotics, antidepressants, and other psychiatric 
drugs, particularly in dopaminergic and serotonergic pathways.9 Few of these candidate genes, 
however, have been proven to be significantly associated with psychiatric disorders when studies 
in large genome-wide association studies.11,12 Using a genome-wide association study conducted 
by the Psychiatric Genetic Consortium and the 1000 Genomes Project, Johnson et al. tested 25 
candidate genes historically associated with schizophrenia and found they were not significantly 
associated with schizophrenia any more than non-candidate control genes.11 This finding 
supported a similar study conducted in 2012, which compared 732 hypothesis-driven candidate 
genes for schizophrenia to the International Schizophrenia Consortium’s GWAS. No significant 
enrichment was found for these candidate genes.12 Border et al. conducted a similar study in 2019, 
examining 18 highly studied candidate genes hypothesized to be associated with depression, 
finding no significant associations.33 
2.1.2.1 Linkage Analyses 
Linkage analysis, linkage disequilibrium mapping, and association analysis were used to 
find chromosomal locations of variation associated with psychiatric disorders.9 Early linkage 
analysis studies were small scale, but eventually were performed on larger samples.34 The first 
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such linkage study was performed on an Amish pedigree in 1987, linking bipolar disorder to a 
region on 11p;10 however, replication of this and later linkage studies was difficult, due to the small 
effects of each individual risk variant and the genetic heterogeneity.9,35 A more recent study by Ng 
et al. in 2009 used a genome scan meta-analysis including 7413 cases of schizophrenia or related 
disorders and found evidence for linkage on 2q, supporting the same team’s earlier finding of 
linkage on 2q in 2003.36  
Psychiatric disorders are complex, genetically heterogeneous, and have variable 
penetrance and expressivity, making linkage and association analyses less than ideal for 
identifying associated genes.9  
2.1.3  Genome-Wide Association Studies 
Since the first family study on schizophrenia by Rudin in 1916, researchers have 
recognized that psychiatric disorders do not follow Mendelian inheritance.37 The difficulty 
replicating associations and the conflicting findings in different studies revealed the complex, 
multifactorial nature of psychiatric conditions.19 Because complex psychiatric disorders are 
influenced by combinations of many loci, each with small effects, large sample sizes are needed 
to find these loci. The development of databases of genetic information, along with collaborative 
efforts, allow for larger sample sizes, enabling more powerful analyses.9 
With the completion of the Human Genome Project in 2003 and subsequent technological 
advances, including easier, faster, and cheaper sequencing methods, researchers could perform 
genome-wide association studies (GWAS), allowing for the identification of hundreds of common 
single nucleotide polymorphisms (SNPs) and rare copy number variants (CNVs) involved in a 
variety of processes and pathways related to pathophysiology of psychiatric disorders.9  
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Pathway analyses implicate disease-associated genes in several types of pathways. 38,39 A 
meta-analysis by Wray et al. identified 44 variants associated with major depression risk; many of 
these variants were found in genes involved in regulatory networks, FMRP binding, synapse 
development and action, neuronal morphogenesis, differentiation, and maturation, calcium 
channels, immune response, and the retinoid X receptor.38 Meta-analysis of GWAS of bipolar 
disorder and schizophrenia identified genes involved in circadian rhythm, immune systems, 
regulation of gene expression, synaptic plasticity, and neurodevelopment.39  
2.1.3.1 Gene Expression Studies  
The majority of identified psychiatry-related polymorphisms lie in non-coding regions, so 
gene expression studies are used to elucidate the functionality of these genetic variants.40 Gene set 
enrichment analysis (GSEA) is a method used to determine if significant differences in gene 
expression are present between two different phenotypes, i.e. affected versus unaffected.41 GSEA 
has demonstrated the most significant enrichment of genetic variants related to psychiatric 
disorders in cortical tissues, particularly the prefrontal and anterior cingulate cortex, and that 
molecular pathways related to synaptic plasticity are highly enriched.40,42 Other gene expression 
studies have found neurons are the cell types affected by some of the identified genetic variants, 
rather than astrocytes, microglia, or oligodendrocytes.38 Gene expression studies of post-mortem 
brain tissue have illuminated functional effects of psychiatric disease-related SNPs, including post-
transcriptional gene expression regulation, alternative splicing, and transcriptional regulation.40 
Darby et al. found that ribosomal genes were overexpressed in post-mortem brain tissue of 
individuals with a psychiatric disorder and that genes related to neuronal processing, signaling, 
endocytosis, and antigen processing were under-expressed.43 
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2.1.4  Copy Number Variants 
Several rare CNVs, some large, have been associated with schizophrenia, bipolar disorder, 
and other neurodevelopmental disorders.44 The first CNV associated with schizophrenia was the 
22q11.2 microdeletion, causing DiGeorge syndrome; approximately one-third of individuals with 
the CNV developing schizophrenia or schizoaffective disorder.45 The 22q11.2 microdeletion was 
later found to be associated with ADHD, anxiety, and autism spectrum disorder as well.46 De novo 
CNVs have been found to be more strongly associated with sporadic schizophrenia than rare, 
inherited CNVs; in familial cases of schizophrenia, however, the rare inherited CNVs are more 
strongly associated, as would be expected.47 These rare CNVS, including 1.q21.1, 15q13.3, and 
22q11.2 deletions and 1q21.1, 15q11.2-q13.1, and 16p13.1 duplications, are somewhat less rare in 
other neurodevelopmental disorders, besides bipolar disorder.47  
2.1.5  Epigenetics 
Many studies of the effects of epigenetics on psychiatric conditions have been undertaken, 
illuminating some of the mechanisms by which environment and genetics interact in psychiatric 
pathophysiology. Tomassi et al. found childhood trauma affected methylation of several genes 
differently in healthy subjects than in subjects with first-episode psychosis.48 The authors 
identified global hypomethylation, as well as differences in expression of specific genes in subjects 
with childhood trauma and first-episode psychosis versus healthy subjects. Other adverse life 
events such as parental loss, low socioeconomic status, and prenatal exposure to maternal stress 
can affect regulation of the stress hormone system, a possible explanation for how these events 
increase risk of developing psychiatric disorders, especially anxiety and depression.49 
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Furthermore, because the majority of SNPs found to be associated with psychiatric disorders lie in 
non-coding regions, these regions may be affecting development of disorders through epigenetic 
means, modifying the effects of life events on gene regulation.50  
2.1.6  Autism Spectrum Disorders 
Individuals with autism spectrum disorders are frequently seen in pediatric genetic clinics, 
in part due to the difficulty determining the causes of individuals’ conditions, hopes for 
interventions guided by genetic findings, concerns about recurrence, and the genetic conditions 
that often co-occur with ASDs.51,52  
Rare CNVs and single nucleotide variants have been implicated in development of ASD, 
along with more common multifactorial factors and polymorphisms.53,54 Individuals whose ASD 
is thought to be caused by rare gene variants and CNVs often have a syndrome that causes other 
psychical, behavioral, or intellectual symptoms; this is termed “syndromic autism.”54 Typically, 
these rarer variants have larger effects than the more common variants, which combine with other 
variants or factors.53,54 Using SNP arrays and WES, Leblond et al. found more rare CNVs in exons, 
more homozygosity of rare deleterious variants, and higher inbreeding status in individuals with 
autism than controls.53 A GWAS of information from the Psychiatric Genomics Consortium and 
the Danish iPSYCH project identified multiple loci significantly associated with ASDs.54 
Enrichment analysis by this study also revealed that some of the common variants associated with 
ASD are in the same genes as rare variants associated with ASD.54  
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2.1.6.1 Genetic Testing for Autism Spectrum Disorders 
Genetic counselors often see prenatal or preconception patients who have a previous child 
with ASD or a family history of ASD. Several national professional organizations recommend 
Fragile X testing and microarray as front-line evaluations for children with ASD.55 Increasingly, 
medical geneticists are ordering whole exome sequencing (WES) for individuals with ASD, as 
diagnostic yields of WES for individuals with neurodevelopmental disorders and/or ASD are 
comparable or better than microarrays.51 The diagnostic yield of microarrays ordered for 
individuals with either developmental delay, intellectual disability, ASD, or multiple congenital 
anomalies is 15-20%, whereas whole exome sequencing for individuals with any of these 
neurodevelopmental disorders is 26-29%.51 For individuals with ASD specifically, the diagnostic 
yield of microarrays is 7-14%, and 8-20% if WES is ordered.51  
With many overlaps found between ASD and other psychiatric disorders, ASD is 
increasingly recognized as not genetically and etiologically distinct from other disorders – 
diagnostic criteria and conceptualizations are beginning to evolve.52,56 The DSM-5 eliminated 
subdivisions such as Asperger Syndrome in favor of autism spectrum disorder, which reflects the 
continuum along which individuals with autism may fall.55 The diagnostic criteria for ASD also 
includes symptoms such as “neurodevelopmental, mental, or behavioral disorder” when 
determining severity, acknowledging their common co-occurrence.55  
2.1.7  Developmental Brain Disorders 
A categorization of Developmental Brain Disorders (DBDs) encompasses all 
developmental, neurological, and psychiatric conditions that have impairments of cognition, motor 
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development, language, and behavior. This broader categorization reflects the idea that these 
conditions have varying degrees of dysfunction along a continuum of traits.52,56  
Finucane et al. recommends study of DBDs using quantitative measurements of these traits, 
rather than dichotomous clinical diagnostic boundaries.52,56 ASD and psychiatric or 
neurodevelopmental disorders co-occur often and share many of the same risk factors and genetic 
associations, so the distinction between DBDs may impair calculations of recurrence risks, and 
association studies could be more effective by reducing this separation.56 Chaste et al. analyzed 
the Simons Simplex Collection for associations between SNPs and autism spectrum disorders in 
2015.57 The authors found that sub-phenotyping within ASD did not increase the power of 
significant association signals, showing that distinctions between different phenotypic 
presentations along a spectrum may not improve discovery of associated genetic variants.57 In 
2016, Gonzalez-Mantilla et al. also found that consideration of brain-related disorders as a group 
increased discovery of novel candidate genes.58  
Distinctions between ASD, MDD, schizophrenia, epilepsy, and other DBDs may in fact 
impair interpretation of pedigree and variant analyses.56 If an individual has a family history with 
different psychiatric disorders, a genetic counselor may not recognize that although there may not 
be multiple individuals with the same diagnoses, there could be a familial or heritable susceptibility 
to psychiatric disorders in general.56,57,59,60 Similarly, if studies do not group psychiatric disorders 
when analyzing relationship between variants and psychiatric conditions, there may not be enough 
statistical power to identify true associations, whereas combining multiple disorders in the analysis 
could enable identification of variants that increase risk for multiple types of psychiatric 
conditions.58,59  
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Recurrence risks are also being redefined as distinctions between DBDs are rethought – if 
a family has one child with ASD, they have a 10% chance of having another child with ASD and 
a 38% chance of having another child with any neurodevelopmental or psychiatric disorder.61 
Childhood-onset disorders, such as tics, ADHD, intellectual disability, or oppositional disorders, 
are most strongly associated with ASD, while schizophrenia, affective disorders, and anxiety 
disorders are also associated, but to a lesser degree.61 Findings like this can allow genetic 
counselors to more accurately provide recurrence risk information and discuss patient pedigrees. 
The basis of this new conceptualization of psychiatric and neurodevelopmental disorders 
lies in the overlaps of genes and pathways implicated in their pathophysiologies, as well as their 
common co-morbidities.56 For example, several studies have found shared genetic associations 
between depression, bipolar disorder, schizophrenia, autism, ADHD, epilepsy, and intellectual 
disabilities.40,41,62 Correlations between major depressive disorder and body mass index, sleep 
quality, and educational attainment (although not IQ) provide new areas to investigate for possible 
etiologies and interventions.38 Depression has also been linked to alcoholism historically by 
clinical presentations of comorbid major depressive disorder and alcohol dependence, and more 
recently by association of alcohol dependence with MDD polygenic risk scores calculated using 
the Psychiatric Genomics Consortium’s meta-analysis.63,64  
2.1.8  Polygenic Risk Scores 
As there are many risk factors yet unidentified for psychiatric conditions, risk calculations 
are complicated. Research is, however, attempting to clarify these risks, with goals of developing 
polygenic risk scores with more predictive power, as well as polygenic risk scores encompassing 
non-genetic and genetic factors.65 Because schizophrenia, bipolar disorder, and ASD have such 
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high heritabilities (73-90%, 80-85%, and 64-91%, respectively) they may be more suitable for 
polygenic risk scores than other, less heritable psychiatric disorders, such as major depression and 
generalized anxiety disorders.27,29,30,31,32,66 Large sample sizes are necessary for accurate risk 
prediction, so as more individuals are enrolled in studies and more samples are collected, current 
risk estimates will become more accurate and clinically relevant.67 Researchers have calculated 
polygenic risk scores, but further studies of accuracy, utility, wide applicability, and replicability 
will be important for decisions about clinical use.68,69 Musliner et al. used genotype information 
from the Danish iPSYCH2012 study and the Psychiatric Genomics Consortium to calculate 
polygenic risk scores for major depression, bipolar disorder, and schizophrenia.70  They found that 
an increase of one standard deviation in polygenic risk scores corresponded to a 30% increase in 
risk for major depression, 5% increase in risk for bipolar disorder, and 12% increase in risk for 
schizophrenia.70  
De Jong et al. analyzed polygenic risk scores in a 260-person pedigree with approximately 
one-third of individuals diagnosed with either major depression or bipolar disorder.68 Anticipation, 
ascertainment effects, and assortative mating, with married-in individuals more likely than the 
general population to have a psychiatric condition, may have contributed to the observed increase 
of psychiatric disorders over generations.68 The authors concluded that polygenic risk scores in 
this study were primarily useful for identifying effects and patterns of the anticipation and 
assortative mating.68 The International Society of Psychiatric Genetics has determined that there 
is not currently clear clinical utility for such polygenic risk scores, as part of their recommendations 
regarding psychiatric genetics clinical practices.69  
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2.2 Pharmacogenetics 
Increased knowledge and research in pharmacogenetics is becoming an increasingly 
important factor in psychiatric genetic counseling, particularly as precision medicine is 
increasingly strived for in research and clinical practice. The Precision Medicine Initiative and the 
All of Us Research Program are large scale efforts to gather physical samples and health 
information from individuals across the nation, with the intent to better tailor research and 
treatment to individuals and groups.71,72 The All of Us Research Program is particularly aiming to 
include individuals from populations and communities that have historically been 
underrepresented in research.72 This will enable more accurate studies and treatments for people 
outside of the most common research populations. The Precision Medicine Initiative aims to use 
its wide reach to enable studies with large sample sizes to develop treatment, therapies, 
preventions, and accurate diagnoses to more effectively help individuals based on their specific 
characteristics, such as genotypes.71  
CYP2C19 and cytochrome P450 variations for example, have been shown to affect 
metabolism of several different drugs, including antidepressants and antipsychotics.73,74  Although 
there is some understanding of variants’ effects on drug metabolism, tests to assess drug suitability 
based on genotype are not currently routinely used in psychiatry, partly due to the paucity of large 
studies of testing utility, efficacy, and reliability.75,76,77,78 Although there are approximately 40 
commercially available pharmacogenetic tests, only nine have been subject to published clinical 
studies, and there is wide variability in the variants and genes assessed by different test kits.79,80,81 
Randomized controlled trials have been performed for five of these kits: GeneSight, CNSDose, 
Genelex, Neuropharmagen, and NeuroIDgenetix.81 These trials found borderline significant 
increased response rates for individuals who underwent pharmacogenetic testing, higher rates of 
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remission and response, and somewhat lower fewer side effects, although not all of these trials 
used power analysis to estimate required sample size, blinded prescribers and raters, or provided 
information about individuals who dropped out of the trials.81  
Identification by genetic studies of potential targets for new drug therapies is highly 
anticipated. In 2017, Pan et al. identified metabolic abnormalities in the cerebrospinal fluid of 21 
out of 33 patients with treatment-refractory depression, particularly deficiencies in 
tetrahydrobiopterin, a cofactor required for synthesis of serotonin, and 5-MTHF, a product of folic 
acid required for formation of amino acid methionine.82 When synthetic analogues of the patients’ 
deficient biochemicals were supplemented (sapropterin and folinic acid) patients improved 
significantly. Individuals who had been catatonic or had recurrent suicidal ideations and suicide 
attempts even after numerous trials of antidepressants, electroconvulsive shock therapy, and other 
interventions, had reduced depressive symptoms after supplementation, some with full 
remission.82 Identification of associated gene variants could allow future development of tests to 
determine if individual patients could be helped by this method of supplementation.82 The success 
of this approach exemplifies the novel methods of psychiatric pharmacotherapy that can arise from 
new research into the genetic etiologies of psychiatric disorders. 
SNPs associated with side effects of antipsychotics, antidepressants, and other medications 
have also been discovered.83 Other pharmacogenetic studies involve identifying genetic predictors 
of treatment response or prognosis.84,85 Zwicker et al. developed a polygenic risk score calculation 
for C-reactive protein that was associated with an improved response to escitalopram and worsened 
response to nortriptyline.85 This finding also points toward investigation of the effects of 
inflammation on antidepressant response. Many studies are searching for genes and loci associated 
with effects of lithium treatment on bipolar disorder, but conclusive findings predicting treatment 
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response have not been proven.85 Not all studies are focused on response to medication - Roberts 
et al. suggested associations between genes and psychological therapy outcomes.86 As more 
findings enable prescribers to select the most suitable drug and therapy treatments, psychiatric 
genetic counseling will likely expand to regularly include pharmacogenetic testing. 
2.3 Psychiatric Genetic Counseling 
2.3.1  History of Psychiatric Genetic Counseling 
Psychiatric genetic counseling grew out of early acknowledgement of heritability of 
psychiatric disorders, identification of loci and genes associated with psychiatric disorders, and 
understanding that genetics and treatment interact.3 As information became available, psychiatric 
genetics became of interest to genetic counselors and their patients. A survey of the National 
Society of Genetic Counselors in 1995 revealed that 96% of respondents expected growth of the 
field of psychiatric genetic counseling.87 Finn and Smoller predicted in 2006 that identification of 
risk genes would increase demand for genetic counseling and explored possible roles of genetic 
counseling in psychiatry.88 The authors identified potential issues, particularly the uncertainty of 
risk estimates and questionable utility of testing, and espoused the necessity of genetics education 
for clinicians.88 Beliefs about causes of mental illness have been shown to affect adaptation to 
illness, indicating that education and/or counseling may benefit patients.89 Phelan et al. used the 
1996 General Social Survey and the Genes, Disease, and Stigma study to look at associations 
between how people perceive the genetic etiologies of depression and schizophrenia and their 
perceptions of treatment recommendations and effectiveness.89 The 1996 General Social Survey 
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presented vignettes describing individuals with schizophrenia or depression to over 600 randomly 
chosen respondents nationwide. Respondents answered how likely they thought it was that the 
mental health issues described had a genetic cause, what their treatment recommendations were, 
and how effective they though the treatment would be.89  The Genes, Disease, and Stigma study 
was conducted similarly, but each vignette included a hospital expert attributing the individuals’ 
mental illness to genetic factors, partly to genetic factors, or not due to genetic factors. Respondents 
answered what their treatment recommendations were and how effective they though the treatment 
would be. The authors determined that perceptions of genetic causes of mental illnesses appeared 
to encourage individuals to seek more extreme interventions, such as medication or hospitalization, 
as well as lead to doubtful expectations of intervention effectiveness.89 This study suggested that 
knowledge of genetic causes of psychiatric conditions may increase individuals’ likelihood of 
seeking treatment for their mental illnesses.89 Lyus 2007 surveyed individuals with schizophrenia 
and their family members about their awareness of genetic counseling and how useful they thought 
it could be.90 Lyus found the majority of participants thought genetic counseling would be useful 
to them, and that none of the individuals with schizophrenia and only 5% of their relatives had 
received genetic counseling.90  
The British Columbia Provincial Medical Genetics program (BCPMG) was formed in 
1968, and as the sole provider of psychiatric genetic counseling in British Columbia, a study of its 
referrals for psychiatric genetic counseling due to a primary indication of schizophrenia provided 
a good indication of psychiatric genetic counseling demand over approximately four decades.91 
Between 1968 and 2007 in British Columbia, there were 288 referrals for psychiatric genetic 
counseling.91 These referrals usually involved a relative of an affected individual and were 
typically for preconception genetic counseling. Referrals peaked between 1988 and 1992, possibly 
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due to the launch of the Human Genome Project or publicized research linking schizophrenia with 
a location on chromosome 5. Referrals did not increase over time as expected by the authors, 
perhaps due to lack of awareness, access, stigma of mental illness, or other healthcare professionals 
providing genetic counseling.92 
2.3.1.1 Psychiatric Genetic Counseling Clinics 
Austin et al. in 2008 investigated the usefulness of psychiatric genetic counseling for 
unaffected parents of individuals with psychotic disorders and found that almost all participants 
found the genetic counseling session useful, and their concerns about recurrence were reduced.3 
Patients and family members were interested in genetic counseling for psychiatric disorders, but 
few utilized the psychiatric genetic counseling that was available, such as that at the 
BCPMG.12,86,87,93 Positive outcomes, high demand, low supply, and assumed lack of awareness of 
how to access the service, led to the opening of the first clinic specializing in psychiatric genetic 
counseling in 2012, in British Columbia.4  
There are currently two specialized psychiatric genetic counseling clinics – one in Canada, 
and one in the United States – but genetic counselors in other clinics also provide psychiatric 
genetic counseling.94 According to the National Society of Genetic Counselors 2019 Professional 
Status Survey, there are fifteen genetic counselors whose primary specialty is psychiatric genetic 
counseling, making up 1% of the genetic counselors in the survey.95 Without widely accepted 
polygenic risk score calculations and guidelines for genetic testing for psychiatric conditions, 
genetic counselors focus more strongly on the psychological impacts of understanding the 
heritability of mental health disorders and discussion of recurrence risks based on family 
history.1,59   
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2.3.2   Outcomes and Practice 
Although psychiatric genetic counseling is a recently developed field, studies have been 
done to assess its utility and efficacy. In 2018, Low et al. used a survey to assess the perceived 
preparedness of 286 current students and recent graduates of genetic counseling training programs 
to provide psychiatric genetic counseling.17 Two respondents expressed that psychiatric genetic 
counseling or education about psychiatric genetic counseling may not be appropriate without the 
availability of further genetic testing and concrete recurrence risk information.17 Some genetic 
counselors have reported hesitancy, or feelings that the information’s complexity and uncertainty 
could be confusing for patients, particularly without adequate time to work with patients.17,96 
Nevertheless, when Hippman et al. surveyed 37 patients with serious mental illnesses after they 
received genetic counseling, twice as many patients reported being unconcerned with uncertainty 
as reported being concerned, and they found the genetic counseling helpful.96 Despite the 
limitations of time, concrete risk numbers, and clinical use of genetic testing for psychiatric 
disorders, genetic counseling can be beneficial.96  
Genetic counseling also clarified perceptions of risk for patients and family members. 
Individuals tended to overestimate recurrence risks.96 In a study of parents of individuals with 
psychotic disorders who received genetic counseling, almost all found the genetic counseling 
useful, reported reduced concern for other relatives, had higher perceived control, and had an 
improved understanding of mental health.3  
Alleviation of guilt and shame, relief at finding an explanation, and increased comfort and 
willingness to discuss mental health have been significant psychological benefits of psychiatric 
genetic counseling, demonstrated in studies of psychiatric genetic counseling clinics.3,4,16,96,97,98 
Patients’ empowerment and self-efficacy were also improved, both in psychiatric genetic clinics 
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and in prenatal counseling.99 Costain et al. studied 35 subjects with schizophrenia before and after 
genetic counseling.4 Genetic counseling improved these subjects’ accuracy of recurrence risk 
estimation, understanding of the etiology of schizophrenia, and reduced stigma and blame.4 
Costain et al. conducted another, similar study, on 78 family members of individuals with 
schizophrenia.100 Post-counseling, these family members also had improved knowledge and 
decreased stigma.100  
Feelings of family vulnerability and use of coping mechanisms were examined by Peay et 
al. using interviews with 48 individuals with bipolar disorder, as well as with their parents and 
siblings.101 Participants indicated desire and attempts to modify risk for relatives and used 
monitoring and cognitive distancing to cope with feelings of vulnerability.101 Parents with bipolar 
disorder themselves reported monitoring their children and feeling more control after genetic 
counseling, but no reduction in worrying.102 Families and affected individuals thought education 
and psychological support were useful but were uncertain about the benefits of risk assessment. 
90,101,105 These findings suggest that focusing on causes of mental illness, risk modification options, 
reproductive options and decisions, early intervention, and healthy coping mechanisms are some 
areas in which psychiatric genetic counseling could help families. 
There can be drawbacks to discussing psychiatric genetics as well, such as fear, fatalism, 
over-medicalization, “geneticization,” and increased anxiety.12,103,104 Parents of children with 
22q11 deletion syndrome reported that risk of psychotic illness was “their greatest source of 
anxiety.”105 Most of these parents were not provided information about association with 
psychiatric disease at time of diagnosis, and rarely after diagnosis.105 Instead, parents reported 
gathering much of their information from non-medical sources, especially the internet.105 The 
finding that oversimplified ideas about risk were associated with deciding to have fewer children 
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and positive attitudes toward genetic testing emphasizes the necessity of ensuring patients and 
their families are fully informed.106 Furthermore, some patients find that a greater understanding 
of how psychiatric illnesses develop is helpful in reducing the stigma of mental illness.2 Other 
patients may find that genetics’ role in mental illness and the classification of “disease” is 
frightening.12,106 These studies highlight the need to improve information, resources, and support 
for families with psychiatric disorders.  
Some resources have been created to help genetic counselors learn to provide this 
information and support, such as Jehannine Austin’s continuing education activity for healthcare 
professionals to increase their understanding of mental illnesses and improve patient experience.107 
In this activity, she introduced genetic counseling and psychiatric genetic counseling, then used 
her experience from the British Columbia psychiatric genetic counseling clinic to describe how 
one should ascertain a patient’s current understanding and perceptions about their mental health 
and mental health in general, as insight into the patient’s mindset and any misconceptions aid in 
tailoring the session toward their situation, interest, and knowledge level, as well as correcting 
misconceptions. She also explains that one should gather tailored personal and family history 
information to allow for discussion of possible contributing factors to psychiatric disorders, 
including heritability, as well as strategies for treating, protecting, or dealing with their mental 
health. Along with discussing recurrence risks and other factual information, she describes 
counselors’ aim to identify and address emotional issues around patients’ or family members’ 
psychiatric conditions. Austin also explained that psychiatric genetic counseling can lead to 
increased empowerment and self-efficacy as well as increased willingness to pursue talk therapy 
and medications.107  
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2.3.3  Effects on Management 
2.3.3.1 Management of Nonpsychiatric Multifactorial Conditions 
As few studies have measured the effects of psychiatric genetic counseling on adherence 
to or initiating treatment, effects of genetic information about other complex diseases may provide 
useful information. Vorderstrasse et al. evaluated how personalized counseling about risk 
assessment for US Air Force retirees and beneficiaries at risk for type 2 diabetes and coronary 
heart disease along with health coaching affected adherence to health recommendations.108 Half 
of the 200 participants’ risk counseling involved genetic testing. The study suggests personalized 
risk assessment may increase adherence, and that using genetic testing to further personalize the 
assessment may increase adherence even more.108  
Dar-Nimrod et al. found that individuals who learned about genetic effects on obesity 
subsequently ate more, suggesting the influence of genetic fatalism.109 Conversely, patients told 
they did not have genes increasing their predisposition to obesity considered health actions less 
important and chose unhealthier foods, suggesting influence of genetic invincibility.110 Ideas about 
genetic etiology influenced how much control individuals felt over their weight, and therefore 
influenced how much they ate.109,110  
A 2013 study of carriers of genetic risk factors for melanoma revealed that following 
delivery of results, unaffected carriers adhered better to recommendations for skin examinations, 
while noncarriers’ adherence decreased.111 Affected carriers’ and noncarriers’ adherence did not 
change significantly. In 2015, Aspinwall et al. measured perceived control ratings in individuals 
with positive family histories of melanoma.112 The genetic counseling sessions in this study 
emphasized ways to reduce risk and detect melanoma early and explained residual risk for 
noncarriers.112 This focus on risk education and helpful actions may explain why noncarriers and 
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unaffected carriers reported increased perceived control, in addition to carriers. Approximately 
45% of participants reported increased perceived control, while only 16.67% reported decreased 
perceived control.  
Cameron et al. discusses strategies to present information about genetic testing and risk-
reducing or -enhancing behaviors to individuals with an increased risk of colon cancer. Different 
modes were used to provide information regarding low-fat diets’ effect on risk given genotype. 
Recipients of all modes reported higher comprehension and higher belief that low-fat diets reduce 
risk of colon cancer, as well as lower perceived risk from positive test results.113  
Although it is not multifactorial, Marteau et al. found in another study that patients with 
clinically-diagnosed familial hypercholesterolemia and their families did not feel less control 
following genetic testing and did not change adherence.114 Individuals with positive genetic testing 
did have altered perceptions of cholesterol-lowering methods, ascribing more importance to 
cholesterol-lowering medications and less importance to diet.114 These studies of nonpsychiatric 
conditions reveal an important consideration for psychiatric genetic counseling: delivering 
information about nongenetic etiologies and risk reduction methods along with genetic etiologies 
and genetic test results may reduce patients’ feelings of fatalism or genetic determinism. 
2.3.3.2 Management of Psychiatric Conditions 
Of course, obesity, melanoma, and colon cancer each have some specific guidelines to 
reduce risk. The National Comprehensive Cancer Network, for example, has published guidelines 
for evaluation, surveillance, and management of individuals at increased risk for colon cancer.115 
Although there are not clear-cut guidelines on risk-reduction methods for unaffected or mildly 
affected individuals regarding psychiatric disorders, there are some recommendations of things 
that may be done or avoided to adjust risk. Basic self-care such as healthy eating, exercise, and 
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good sleep habits are suggested, as well as more psychological self-care, such as meditation, self-
reflection, healthy social connections, and other methods of coping with stress or struggles.116,117 
Pursuing talk, music, art, bright light, or other therapy can be valuable for individuals at risk for 
mental illness.118 Individuals at higher risk for psychosis may wish to avoid certain drugs, illicit 
or prescription, known to trigger episodes of psychosis, particularly methamphetamines, cannabis, 
and cocaine.119  
Awareness of risk for psychiatric illnesses can also prompt individuals or family members 
to be alert to early signs of disease.120,121,122,123 Early detection and intervention, as well as 
familiarity and comfort discussing mental illness, can have significant positive effects on 
prognosis.120,121 Lebowitz et al. assessed participants with depressive symptoms’ ideas about 
causes of their mental health symptoms and expected duration of mental health symptoms.104 The 
authors found that individuals with depressive symptoms who endorsed biochemical and genetic 
etiologies of depression reported longer expected symptom duration than those who assigned 
higher attributions to other etiologies; however, when subsequent education emphasized the 
pliable nature of genetics’ and neurochemistry’s effects, participants’ pessimism, agency, and 
hopelessness improved.104 These attitudes can be very important to patient outcomes. Hippman et 
al. divided participants with diagnoses of schizophrenia, bipolar disorder, or schizoaffective 
disorder into three groups: one group received genetic counseling, one group read an educational 
booklet with the same information the genetic counselor provided, and one group was put on a 
waitlist.16 Each group completed a questionnaire prior to receiving genetic counseling or the 
educational booklet (baseline), immediately after the intervention, and one month after 
intervention. The waitlist group was assessed with questionnaires for their baseline and pre-
intervention measures on the same day. The study demonstrated that both genetic counseling and 
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an educational booklet increased patient knowledge, but only genetic counseling improved the 
accuracy of patients’ risk perceptions.16  
Patients with schizophrenia found to have no clinically relevant genetic variant initially 
overestimated recurrence risk, had high concern about this risk, had incorrect knowledge about 
schizophrenia, and felt self-blame.16 Post-counseling assessments showed improvement in all 
measures. Patients were satisfied and saw the need for this counseling. Family members of 
individuals with schizophrenia also overestimated recurrence risk, and after counseling had more 
accurate risk perceptions and lower concern about recurrence, along with increased knowledge 
and decreased stigma.16  
2.4 Provider Attitudes 
With possibilities of both positive and negative effects on patients, some genetic counselors 
are hesitant to adopt psychiatric genetic counseling.17,96 Furthermore, although information about 
risk and recurrence is increasing, specific risk numbers are difficult to determine.69,96  
A study focusing on recent graduates and current students found significant associations 
between perceived preparedness to deliver psychiatric genetic counseling and frequency of 
psychiatric genetic counseling instruction, active opportunities to practice, and education about 
referrals and patient resources.17 Approximately half of the respondents (48.5%) reported feeling 
“somewhat” or “very” prepared to provide psychiatric genetic counseling. However, many of the 
recent graduates (37.6%) felt their training programs’ education about psychiatric genetics was 
“inadequate.” Those who reported learning about providing patient resources and referrals were 
more likely to feel prepared for psychiatric genetic counseling. Of the practicing respondents, 
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approximately half had provided resources or referrals.17 From these findings, it is clear that further 
development and dispersal of patient-oriented resources, and education regarding these resources, 
would be beneficial to genetic counselors’ preparedness. Currently, there are few resources for 
patients with rare CNVs and SNVs or newly found common variants. The study also examined 
stigma and stereotype; respondents who had personal experience with mental health issues or 
exposure via volunteering, family members, friends, or other means presented lower 
measurements of desire for social distance from individuals with psychiatric disorders.17  
One issue some genetic counselors identify in psychiatric genetic counseling is that typical 
genetic counseling systems often involve a single appointment. They worry that without a longer-
term relationship or multiple sessions, such a complex, personal, and sensitive subject cannot be 
addressed with the proper depth or therapeutic techniques.17  
Other studies have found that attitudes toward and perceptions of mental illness greatly 
impact how healthcare providers interact with patients in regard to mental health.124,125,126 
Perceived usefulness and perceived complexity also influence decisions to adopt newly developed 
methodology, more so than knowledge and ease of use, as determined by surveying members of 
the NSGC Cancer Special Interest Group.127 This survey identified that more experienced genetic 
counselors were more likely to intend use of refined cancer risk estimates than more recent 
graduates.127 It is possible this is due to differences in confidence of clinical skills and patient 
interactions. Evaluation of physicians’ decisions to refer patients to psychiatric genetic counseling 
showed that referrals were influenced by ideas about the purpose of psychiatric genetic counseling 
and patient cues, as well as confidence in knowledge base.125128  
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2.5 Continuing Education 
With genetic counseling training programs providing different types of education and 
practice in the field of psychiatric genetic counseling, and many genetic counselors having 
graduated from programs prior to this era of psychiatric genetics, continuing education and 
exposure to current knowledge is very important. Continuing education is required for 
licensed/certified genetic counselors, but psychiatric genetic counseling may be underrepresented 
in continuing education opportunities. Nonetheless, this emerging field has attention and interest, 
and conferences, online courses, and journal articles are increasingly available.129,130  
The Educational Breakout Session presented by the Psychiatric Special Interest Group of 
the National Society of Genetic Counselors (NSGC) at the 2006 Annual Education Conference 
created a two-part Professional Development series to guide genetic counselors in taking family 
histories and conceptualizing recurrence risks in relation to psychiatric disorders, including case 
simulations.59,60 The uncertainty associated with psychiatric disorders’ etiology, type, severity, 
diagnostic criteria, and risk is an important consideration, but does not preclude benefits from 
genetic counseling. This series recommends discussion of how genetics and environment affect 
development of psychiatric diseases, along with the way these interact.59,60  
Ascertaining a client’s preexisting understanding of the etiology of psychiatric disorders, 
ideas about control over management and risk-reduction, risk perceptions, and attitudes about 
mental illness is necessary to combat misinformation, blame, genetic determinism, and stigma. 
The NSGC Professional Development series reminds genetic counselors that they routinely deal 
with these same issues in relation to other genetically related conditions and can utilize these 
methods and skills throughout genetic counseling, such as contracting, awareness of client 
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reactions, assessing client decision-making methods, assessing client comprehension, and 
anticipatory guidance.   
This series also emphasizes the importance of self-reflection and self-awareness regarding 
attitudes, knowledge, and confidence about mental illness, psychiatric disorders, and their genetic 
etiologies. This will allow genetic counselors to adapt attitudes and practices or seek additional 
education or information as needed. There are suggestions of how to use risk information to assess 
and convey individual risk. This series is a valuable tool for genetic counselors who encounter 
patients with personal or family histories of psychiatric disorders.  
Edwards et al. evaluated the outcomes of communication methods used to discuss risk with 
clients in 28 studies, including studies that used communication models or decision aids.131 The 
majority of these studies addressed risks related to cancer genetics. The authors found that the 
supportive and emotional elements of counseling were more beneficial to clients than the 
educational elements.131  
Of course, genetic counselors are not the only medical professionals who will provide 
information about psychiatric genetics. Education for other healthcare providers is important as 
well – including psychiatrists, primary care physicians, pediatricians, pharmacists, and specialists.  
German et al.’s study of pharmacists compared their training and experience to perceived 
preparedness to provide pharmacotherapy regarding psychiatric disorders.124 The pharmacists with 
specialized training and experience in psychiatric pharmacy reported higher preparedness and 
fewer barriers to providing pharmacotherapy than pharmacists without specialized training or 
experience. Some of the barriers reported were time, lack of a private consultation area, and 
reimbursement for services. Pharmacists with specialized training and experience were more likely 
to provide services to patients with psychiatric disorders.124 These findings highlight the 
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importance of education and training for healthcare professionals who will work with individuals 
with psychiatric disorders. The finding that even pharmacists with training and/or experience in 
pharmacotherapy did not feel prepared to utilize online resources with up-to-date information 
about treating psychiatric disorders reiterates the need for more patient and provider resources 
about psychiatric genetics and associated pharmacogenetics.124  
Professional organizations, such as the International Society of Psychiatric Genetics, have 
developed recommendations for training programs and knowledge for their medical professionals 
to remain up-to-date, relevant, and prepared for the growing field of psychiatric genetics.132 The 
National Society of Genetic Counselors has developed psychiatric genetics resources for provider 
education, such as an online course, “Psychiatric Genetics across Genetic counseling Practice 
Settings,” as well as patient resources, including a section in “Making Sense of Your Genes: A 
Guide to Genetic counseling.”129,133 In this modern era, sources such as webinars, podcasts, blogs, 
social media, and other Internet-based learning have become significant sources of information for 
genetic counselors and other medical professionals.134,135,136 More traditional forms of education 
are, however, still widely used. 
In 2003, Maio et al. found that pharmacists primarily used printed materials for continuing 
education, followed by lectures and seminars, Internet materials, and less frequently, symposia.137 
De Leo et al. assessed physicians’ consultation of websites for medical information.138  Physicians 
reported primarily using targeted websites rather than search engines, particularly secondary data 
sources such as Up-toDdate, Medscape, or Webmd, research databases with access to medical 
journals such as Pubmed or Ovid, specialized sites, or medical web portals such as Mercmedicus. 
The landscape of the internet has changed significantly since 2006, so an update to these 
assessments would be valuable. 
 32 
Grierson et al. touts video-based observation in combination with practice, self-assessment, 
expert feedback, and peer-to-peer feedback for effective improvement in student nurses’ learning 
of clinical skills.139 Internet-based learning for a variety of healthcare professionals had significant 
effects on educational outcomes, more so than traditional instruction.139 Web-based learning 
encompasses a variety of methods, including written text, multimedia, chat or videoconferencing, 
patient cases, and self-assessment.135 Electronic continuing education was effective when it 
involved other components, but not when involving only text. This supports conclusions that 
further engagement or hands-on activity are of considerable importance in education.139 These 
studies all suggest that more interactive, nontraditional training and educational resources are 
necessary to improve clinician knowledge and clinical practice. Increasing the effectiveness of 
continuing education is important for many professions, especially psychiatric genetic counseling.  
Studies of the efficacy and utility of continuing education in medical professions have had 
mixed results. Increased knowledge, skills, attitudes, and patient outcomes have been 
demonstrated, but these do not always correlate with changes to clinical practice.140,141 O’Brien et 
al. found that while interactive workshops led to changes in practice, didactic sessions did not.141 
Forsetlund et al. found educational meetings could improve practice and healthcare outcomes, but 
were not likely to change complex behaviors.142  
In Low et al.’s study, active education and practice in providing psychiatric genetic 
counseling were associated with feeling prepared to engage in psychiatric genetic counseling when 
surveying current students and recent graduates.17 Exposure to clinical observations or practice, 
engagement with individuals with mental illness, and role plays or activities were significant in 
increasing levels of preparedness and reducing stigma towards mental illness.17  
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2.6 Study Goals 
As evidenced in the literature, a wealth of new information is available regarding the 
interaction of genetics and psychiatry. Researchers and clinicians are working to integrate this new 
information into clinical practice, and psychiatric genetic counseling in particular is a developing 
field with significant potential to improve health care for patients with mental illness. Although 
studies have shown the utility of specialized psychiatric genetic counseling, patient and clinicians’ 
interest in psychiatric genetic counseling, and new applications of genetic testing, 
pharmacogenetics, and risk calculations for psychiatric conditions, this thesis project aims to 
investigate genetic counselors’ current practices and confidence regarding psychiatric genetics, as 
well as the factors that affect their practice and confidence, in order to determine what resources 
and information would benefit genetic counselors and their patients with personal or family 
histories of psychiatric conditions. Ideally, this understanding will direct future research on 
development of training programs, continuing education, and patient and provider resources. 
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3.0 Manuscript 
3.1 Background 
The origins of psychiatric disorders have been studied since the inception of the field of 
psychiatry. From observations of familial clustering to early family and twin studies, the strength 
of genetic and environmental contributions has been investigated. Family and twin studies have 
been used to calculate the heritability of psychiatric disorders and autism spectrum disorder, 
finding that schizophrenia, bipolar disorder, and ASD have large genetic sources (approximately 
60-90%), while other conditions like depression and anxiety, are approximately 30-40% 
heritable.29,29,30,31  
Findings from family studies, hypothesis-driven candidate gene studies, and linkage 
analysis studies proved the complex, heterogenous nature of psychiatric disorders.28,29,30,31,35 These 
have been followed by newer methods such as genome-wide association studies, pathway 
analyses, and gene expression analyses, allowing for discovery of genetic variants and epigenetic 
changes associated with ASD, depression, anxiety, schizophrenia, bipolar disorder, and other 
psychiatric disorders.34,38,39,40,41,42,43 Researchers are attempting to clarify risks calculations for 
psychiatric disorders, aiming to improve risk polygenic risk scores and identify risk factors yet 
unidentified for psychiatric conditions.65,66,67,68 Applicability of pharmacogenetic tests to 
psychiatric conditions is also being investigated, with need for more studies of testing utility, 
efficacy, and reliability before widespread use.77,78,77,78,79 Development of new drug therapies 
based on genetic studies is highly anticipated.78  
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With approximately 19% of the United States population suffering from a mental illness 
and increased public health attention, research on psychiatric genetics and care of individuals with 
mental illness are in growing demand.5,8 The role of genetic counselors in psychiatry is growing 
and changing, due to knowledge improving on psychiatric illness pathophysiology, genes, loci, 
and epigenetics involved in mental health, clearer heritability and recurrence risk estimations, and 
pharmacogenomics. With increasing knowledge and public interest in psychiatric genetics, the 
field of psychiatric genetic counseling developed. Dedicated psychiatric genetic counseling clinics 
and genetic counselors in other specialties have begun to work with patients and families with 
histories of mental illness, and studies have revealed positive outcomes of these clinics.3,4,97,98  
ASD is being recognized as having overlapping etiologies and occurrences with other 
neurodevelopmental and psychiatric disorders, and ASD itself is considered a continuum of traits 
and severity.52,56 Developmental Brain Disorders (DBDs) has been proposed as a continuous 
category encompassing all developmental, neurological, and psychiatric conditions that have 
impairments of cognition, motor development, language, and behavior. This new 
conceptualization of psychiatric and neurodevelopmental disorders arose from discovery of 
overlapping genes and pathways implicated in their pathophysiologies, as well as their common 
co-morbidities.52,56  
Although uncertainty is still present in discussions of risk for psychiatric disorders, 
recipients of psychiatric genetic counseling have demonstrated more accurate risk perceptions, 
reduced concern, improved understanding of mental health, as well as alleviation of guilt and 
shame, relief at finding an explanation, and increased comfort and willingness to discuss mental 
health.3,4,97,98,99 Patients’ empowerment and self-efficacy are also improved.99,100 Studies have 
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highlighted the need to improve information, resources, and support for families with psychiatric 
disorders.3,105  
While the provision of genetic counseling for psychiatric genetics is still relatively new, 
studies of genetic counseling for nonpsychiatric multifactorial conditions suggest personalized risk 
assessment for individuals at risk for type 2 diabetes and coronary heart disease may increase 
adherence to treatment protocols, and that using genetic testing to further personalize the 
assessment may increase adherence even more.108 Another study found that patients with familial 
hypercholesterolemia and their families did not change adherence, but did have altered perceptions 
of cholesterol-lowering methods.109 Genetic fatalism and genetic invincibility are concerns, but 
focus on risk education and helpful actions can increase perceived control.110  
Although there are not yet guidelines on risk-reduction methods for individuals identified 
to have increased risk for psychiatric disorders from genetic tests, healthy eating, exercise, good 
sleep habits, meditation, yoga, self-reflection, healthy social connections, and therapy can be 
emphasized to maintain mental health.116,117,118 Awareness of risk for psychiatric illnesses can also 
aid early detection and intervention, as well as familiarity and comfort discussing mental illness, 
can have significant positive effects on prognosis.121,122,123  
With possibilities of both positive and negative effects on patients and uncertainty of risk 
estimates, some genetic counselors are hesitant to adopt psychiatric genetic counseling.17 Low et 
al.’s survey of current and recent genetic counseling students revealed that genetic counseling 
training programs, access to patient resources, and attitudes toward mental health have been shown 
to affect preparedness and willingness to provide counseling for psychiatric genetic disorders.17  
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Conferences, online courses, and journal articles are increasingly available to supplement 
genetic counselors’ knowledge of psychiatric genetics, with professional development series, 
continuing education activities, an online course by NSGC, and patient resources.59,60,129,133 
The purpose of this study is to investigate genetic counselors’ current practices and 
confidence regarding psychiatric genetics, as well as the factors that affect their practice and 
confidence. This will help determine what resources and information would benefit genetic 
counselors and their patients with personal or family histories of psychiatric conditions. 
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3.2 Methods 
3.2.1  Sample 
An anonymous survey was distributed through the National Society of Genetic Counselors 
(NSGC) email listserv in a weekly email notifying the membership of student research surveys. 
NSGC has over 4000 members, but the exact number of members on this email listserv is not 
available.95 The first email went out on June 19, 2019, with a reminder email sent on July 3, 2019. 
All current genetic counselors, regardless of current practice area, were invited to participate 
between June 19, 2019 and July 10, 2019. This study was approved as exempt by the University 
of Pittsburgh Institutional Review Board (IRB), Study #19050028 (see Appendix A for IRB 
approval letter) 
3.2.2  Survey 
A survey containing 25 questions was developed with consideration of several studies that 
also assessed medical professionals’ attitudes, perceived preparedness, and decision-making in 
relation to psychiatric diseases.  
Leach et al.’s 2016 survey investigated how physicians decide whether to refer patients for 
psychiatric genetic counseling, which influenced development on questions about important 
factors in decision-making.125 Phokeo et al. questioned pharmacists’ attitudes toward and 
interactions with patients prescribed psychiatric medications, which, along with a study from 
Durham in 2019 and two unpublished University of Pittsburgh genetic counseling students’ theses, 
informed questions about medical professionals’ practices.126,143 A survey by German et al.  
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completed in 2018 assessed how prepared pharmacists felt to treat patients with psychiatric 
disorders, and Low et al.’s 2018 survey investigated relationships between perceived preparedness, 
attitudes toward mental illness, personal experiences, and training in recent graduates and current 
students of genetic counseling training programs.17,124 Both studies were consulted for 
development of questions about confidence, preparedness, and educational methods. 
The electronic survey was constructed with the University of Pittsburgh Qualtrics system 
and utilized skip logic (see Appendix B for full survey). Demographic information was collected 
first, including gender, graduation decade, region, and specialty. Subsequent multiple-choice 
questions assessed participants’ practices when interacting with patients who have personal and/or 
family histories of psychiatric disorders. For example, participants were asked whether they had 
ever referred a patient for psychiatric genetic counseling. A six-item, 4-point Likert-type scale then 
asked participants to indicate how much each factor listed influenced their decisions about ordering 
genetic testing for psychiatric conditions. For example, participants were asked the level of 
influence of their confidence in their knowledge of psychiatric genetics. A 2-item, 5-point Likert-
type scale then evaluated participants’ confidence regarding psychiatric genetics. Multiple choice 
questions followed regarding genetic counseling training programs and educational resources. An 
optional open-ended question concluded the survey by asking about participants’ views on 
psychiatric genetic counseling’s future. The survey was piloted by members of the thesis 
committee and edited before being distributed. The survey was open for three weeks. 
3.2.3  Data Analysis 
Microsoft Excel and Stata software were used to complete statistical analyses.144 All 
responses were used, including partial responses. Fisher’s exact test was used to determine whether 
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demographic variables were significantly associated with genetic counseling practices, because 
observed values in some groups were below 5. Statistically significant associations were defined 
as those with p-values under 0.05. Descriptive analysis and bar graphs were used to indicate 
response frequencies and percentages. 
3.3 Results 
3.3.1  Demographics 
The survey was distributed to the NSGC Student Survey listserv program, and it received 
108 responses. Because respondents were not required to answer each question, skip logic was 
used, and some individuals did not complete the full survey, different questions received different 
numbers of responses. Almost all (90.74%, n=98) respondents were genetic counselors who saw 
patients, and the other 9.26% (n=10) was in research or laboratory, education, and one responder 
who is not currently practicing as a genetic counselor. Two of the respondents were counselors 
whose specialty was psychiatric genetic counseling.  
The majority of respondents graduated from a genetic counseling training program in the 
last ten years, with 82.86% (n=87) graduating between 2010 and 2019. No respondents graduated 
before 1980, 1.91% (n=2) graduated between 1980 and 1989, 5.71% (n=6) graduated between 
1990 and 1999, and 9.52% (n=10) graduated between 2000 and 2009. 94.29% (n=99) were female, 
3.81% (n=4) were male, and 1.90% (n=2) answered “Other” or “Prefer not to answer.” Regions II 
and IV had the largest percentages, 23.81% (n=25) and 37.14% (n=39), respectively. (Regions 
denotated in Table 1) 
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Table 1: States, Territories, and Provinces in each Region 
Region  
I CT, MA, ME, NH, RI, VT, Canadian Maritime Provinces 
Region 
II 
DC, DE, MD, NJ, NY, PA, VA, WV, Quebec, Puerto Rico, Virgin 
Islands 
Region 
III AL, FL, GA, KY, MS, NC, SC, TN 
Region 
IV AR, IA, IL, IN, KS, MI, MN, MO, ND, NE, OH, OK, SD, WI, Ontario 
Region 
V AZ, CO, MT, NM, TX, UT, WY, Alberta, Manitoba, Saskatchewan 
Region 
VI AK, CA, HI, NV, OR, WA, British Columbia 
 
The breakdown of gender, region, graduation year, and specialty were compared to the 
National Society of Genetic Counselors 2019 Professional Status Survey.95 (Table 2) Genetic 
counselors who graduated between 2010 and 2019 were more highly represented in the thesis 
survey (82.86%) than in the Professional Status Survey (56%), and all other graduation decades 
were underrepresented in the thesis sample. The gender distribution of thesis survey respondents 
was almost equivalent to the PSS. Regions I and V were underrepresented, and Region VI was 
overrepresented in the thesis sample versus the PSS. There was a lower percentage of cancer and 
preconception genetic counselors than represented in the PSS, and a higher percentage of prenatal 
and pediatric genetic counselors and those involved in education. Other specialties were similarly 
represented in both samples. 
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Table 2: Demographic Distributions of Thesis and PSS Respondents 
Year of 
Graduation Thesis PSS 
1971-1979 0.00% 1.00% 
1980-1989 1.91% 4.00% 
1990-1999 5.71% 11.00% 
2000-2009 9.52% 28.00% 
2010-2019 82.86% 56.00% 
Gender Thesis PSS 
Female 94.29% 95.00% 
Male 3.81% 5.00% 
Region Thesis PSS 
Region I 2.86% 7.00% 
Region II 23.81% 21.00% 
Region III 15.24% 12.00% 
Region IV 37.14% 28.00% 
Region V 4.76% 13.00% 
Region VI 16.19% 19.00% 
Specialty Thesis PSS 
Psychiatric 1.90% 1.00% 
Cancer 19.05% 30.00% 
Prenatal 28.57% 18.00% 
Pediatric 20.00% 10.00% 
Preconception 0.00% 2.00% 
Cardiology 1.90% 3.00% 
Specialty 5.71% 5.00% 
General 5.71% 5.00% 
Laboratory 2.86% 2.00% 
Education 3.81% 2.00% 
3.3.2  Practice 
The clinical genetic counselors were then asked about their interactions with patients. 
68.69% (n=68) have never seen a patient whose primary indication was a psychiatric condition, 
and 31.31% (n=31) have. They were then asked how often they discussed or asked about 
psychiatric conditions during sessions. Figure 1 indicates the percentage of respondents who 
always, sometimes, or never discuss patients’ personal or family histories of psychiatric 
conditions, ask about family history of psychiatric conditions, and ask about personal history of 
psychiatric conditions. Counselors report discussing patients’ personal or family history of 
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psychiatric conditions if present more than they report asking about psychiatric conditions in the 
personal or family history.  
The two respondents who are psychiatric genetic counselors always ask about psychiatric 
conditions when gathering history information, and always discuss if psychiatric history is present. 
10% of cancer genetic counselors indicated that they “Never” discuss psychiatric conditions if they 
are present in a personal or family history, as did 4.76% of pediatric genetic counselors. All other 
respondents indicate they “Sometimes” or “Always” discuss if psychiatric history is present. Of 
the nonpsychiatric genetic counselors, adult genetic counselors were most likely to say they 
“Always” ask about psychiatric conditions when taking personal or family history information 
(66.67% and 33.33%, respectively), and cancer genetic counselors were least likely (5% and 0%, 
respectively). 
 
  
Figure 1: Frequency of History-Taking Practices (n=99) 
When asked how they presented risk information to patients, 5.27% (n=5) indicated they 
provide quantitative risk information, such as recurrence risk, 57.90% (n=55) indicated they 
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provide qualitative risk information, 29.47% (n=28) provide both quantitative and qualitative 
information, and 7.37% (n=7) provide other risk information; individuals who selected “Other” 
explained they provide information such as who else in the family should be evaluated by genetics 
or information about complex inheritance. Another individual wrote that they employ the “jar 
model” in explaining risk to patients, which is a method of explaining genetic and environmental 
contributions to multifactorial conditions. The majority of respondents indicated they 
“Sometimes” ask about or discuss histories of psychiatric conditions, which alongside two 
respondents who wrote in that they would tailor the type of risk information discussed based on 
what the patient was interested in hearing, reflects counselors basing questions and discussions off 
of individual patient indications, interests, and time constraints. 
Table 3 describes the percentages of respondents who have referred a patient to a 
psychiatric genetic counselor, disclosed secondary findings related to a psychiatric condition, and 
ordered genetic testing specifically for a psychiatric condition. Few respondents have referred a 
patient to a psychiatric genetic counselor (9.28%, n=9) or ordered genetic testing for a psychiatric 
condition (11.22%, n=11), and 15.31% (n=15) have disclosed secondary findings related to a 
psychiatric condition.  
Table 3: Percent of Respondents Who Have Performed Psychiatric Genetic Counseling Practices 
Practice Yes (%) 
Yes 
(Count) No (%) 
No 
(Count) 
Seen a patient whose primary 
indication was a psychiatric 
condition 
31.31% 31 68.69% 68 
Referred a patient to a 
psychiatric genetic counselor 9.28% 9 90.72% 88 
Disclosed secondary findings 
related to a psychiatric condition 15.31% 15 84.69% 83 
Ordered genetic testing 
primarily for a psychiatric 
condition 
11.22% 11 88.78% 87 
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Respondents then selected conditions for which they had ordered genetic testing, as 
presented in Table 4. Almost half of the respondents (41.90%, n=44) have ordered genetic testing 
for autism, but other conditions were ordered for less often. Tests for dementia (8.57%, n=9) and 
ADD/ADHD (6.67%, n=7) were the next most ordered. A few counselors have ordered tests for 
depression (0.95%, n=1), anxiety (1.91%, n=2), and schizophrenia/schizoaffective disorder 
(2.86%, n=3), but no one had ordered a test for psychosis, bipolar disorder, personality disorders, 
alcohol or substance abuse, or eating disorders. Participants who selected “Other” listed behavioral 
concerns and combinations of psychiatric issues with dysmorphic features or developmental delay.  
Table 4: Percent of Respondents Who Have Ordered Genetic Testing for Certain Psychiatric Conditions 
Condition Percent 
Depression 0.95% 
Anxiety 1.90% 
ADD/ADHD 6.67% 
Schizophrenia/schizoaffective 2.86% 
Psychosis 0.00% 
Bipolar disorder 0.00% 
Personality disorder 0.00% 
Alcohol/substance abuse 0.00% 
Eating disorder 0.00% 
Autism spectrum disorder 41.90% 
Dementia 8.57% 
Other 5.71% 
 
Survey respondents assessed the influence of various factors in their decisions to order 
genetic testing and indicated their responses on a Likert-type scale that ranged from “No Influence” 
to “High Degree.” Approximately half of the respondents answered that relevance to the patient’s 
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primary indication had a high degree of influence on their decisions to order genetic testing, while 
fewer respondents assigned a high degree of influence to confidence in their knowledge base, 
current evidence for psychiatric genetic counseling, or personal and patient levels of comfort with 
discussing mental health. Other factors respondents described in an open text box when “Other” 
was selected were the amount of time in the session, relevance to psychosocial issues, strength of 
the family history of psychiatric disorder, patient’s concerns identified in contracting, the severity 
of the patient’s psychiatric presentation, type of psychiatric conditions in history, and patient’s 
interest or targeted questions. Of those who indicated other, four answered that time considerations 
had an influence. These results are summarized in Figure 2.  
 
Figure 2: Degree of Influence of Various Factors on Testing Decisions (n=95) 
Respondents were then asked to what degree they agreed with statements that they feel 
confident in their understanding of psychiatric genetics and confident they could explain 
psychiatric genetics to a patient. (Figure 3) 65.67% (n=65) responded that they “Somewhat” or 
“Strongly Agree” with the statement “I feel confident in my understanding of psychiatric 
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 47 
genetics,” and 21.21% (n=21) “Somewhat” or “Strongly Disagreed.” To the statement “I feel 
confident I could effectively explain psychiatric genetics to a patient, 73.74% (n=73) of 
respondents answered they “Somewhat” or “Strongly Agreed,” and 14.14% (n=14) “Somewhat” 
or “Strongly Disagreed.” Figure 3 provides more detail, with responses on a Likert-like scale 
ranging from answer choices of “Strongly Disagree” to “Strongly Agree.” The large proportion of 
respondents who agree that they are confident about psychiatric genetics belies the lower 
proportion who have provided psychiatric genetic counseling services and the 19.19% and 23.47% 
of respondents “Never” who ask about family or personal histories of psychiatric disorders, 
respectively. It is also interesting to note that although respondents indicate high confidence, this 
level of confidence was the second-least likely to have a “High Influence” on ordering genetic 
testing for psychiatric disorders.  
 
Figure 3: Degree of Confidence (n=99) 
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3.3.3  Education and Resources 
The majority of respondents, 68.69% (n=68), indicated that their genetic counseling 
training programs had included information about psychiatric genetic counseling. 23.23% (n=23) 
said their training program did not include this information, and 8.08% (n=8) did not remember. 
When asked how this information was provided, 55.77% (n=58) responded that it was presented 
through classes, 11.54% (n=12) through clinical rotations, 3.84% (n=4) through extra-curricular 
activities, 19.23% (n=20) through conferences or seminars, and 9.62% (n=10) through other 
methods, such as simulations of patients, journal articles, NSGC educational tools, and workshops. 
One individual explained that her thesis focused on an aspect of psychiatric genetic counseling. 
Table 5 illustrates the ways instruction was provided based on graduation decade. Only 
one respondent who graduated in the 1990s attended a training program that provided information 
about psychiatric genetics, and that information was provided in classes and clinical rotations. 
Graduates from 2000-2009 also received all of their information from classes and clinical 
rotations. Graduates from the last decade, however, were most likely to receive information about 
psychiatric genetics from classes and conferences or seminars. Information was also provided to 
them in clinical rotations and through extra-curricular activities.  
Table 5: Types of Instruction by Graduation Decade 
 Classes Clinical Rotations 
Extra-Curricular 
Activities 
Conferences or 
Seminars 
1980-1989 0 0 0 0 
1990-1999 1 1 0 0 
2000-2009 5 2 0 0 
2010-2019 52 9 4 20 
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Figure 4 compares the resources used to stay informed about general genetics with the 
resources that would be helpful to stay informed about psychiatric genetics. “Other” resources 
specified by respondents were books, school notes, and the National Coalition for Health 
Professional Education in Genetics website. 
The most frequently selected resources for general genetics and psychiatric genetics were 
journal articles, conferences and seminars, and online courses. Email listservs and discussion 
with colleagues were also frequently chosen as resources for general genetics, but not psychiatric 
genetics. Blogs, social media, podcasts, radio, and television were rarely chosen, by less than 
30% of respondents. The only resources ranked more highly for psychiatric genetics than general 
genetics were online courses and podcasts, radio, and television. 
 
Figure 4: Preferred Genetics Resources 
When asked what kind of information about psychiatric genetics would be most useful, the 
most frequently selected answer was recurrence risks, selected by 90.82% (n=89) of respondents. 
33.67% (n=33) and 36.73% (n=36) selected pharmacogenetics and polygenic risk scores, 
respectively. 22.45% (n=22) said they would case find studies useful, 77.55% (n=76) said 
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information about associations between psychiatric conditions and other patient indications would 
be useful, and 44.90% (n=44) said studies of the utility and efficacy of psychiatric genetic 
counseling would be useful. (Table 6) 
Table 6: Percent of Respondents Who Would Find Certain Types of Information Useful 
Type of Information Percent 
Recurrence risks 90.82% 
Pharmacogenetics 33.67% 
Polygenic risk scores 36.73% 
Case studies 22.45% 
Associations between psychiatric conditions and other patient 
indications (i.e. genetic syndromes, neurodevelopmental disorders) 77.55% 
Studies of psychiatric genetic counseling utility and efficacy 44.90% 
Other 1.02% 
 
Three respondents (3.03%) have taken the NSGC online course “Psychiatric Genetics 
across Genetic Counseling Practice Setting.” 39.40% (n=39) indicated they were aware of the 
course but have not taken it, and 57.58% (n=57) were not aware of the course. 43.43% (n=43) of 
survey respondents said they have attended a speaking event regarding psychiatric genetics in the 
past year, while 56.57% (n=56) have not. 
In response to a question asking what factors would increase their likelihood of discussing 
psychiatric genetics with patients, 61.96% (n=57) selected learning more about psychiatric 
genetics, 53.26% (n=49) selected having more access to patient resources, 57.61% (n=53) selected 
more information about evidence-based practice of genetic counseling, and 18.48% (n=17) 
described other factors, including if they were in a position to have referrals for psychiatric 
conditions, more time to address it in sessions, more conclusive evidence of psychiatric genetics, 
patient questions, support from their boss, relevance to their clinic, more opportunity to practice 
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psychiatric genetic counseling, whether testing for psychiatric conditions would change medical 
management, patient interest, and more awareness of testing and screening options. 
Fisher’s exact tests were performed to determine whether demographic factors (year of 
graduation, gender, specialty, region, attending a training program that addressed psychiatric 
genetics) were significantly associated with provider practices (having seen a patient whose 
primary indication was a psychiatric condition, having referred a patient to a psychiatric genetic 
counselor, having disclosed secondary findings related to a psychiatric condition, having ordered 
genetic testing primarily for a psychiatric condition, and attending a training program that 
addressed psychiatric genetics).  
Year of graduation and having referred a patient to a psychiatric genetic counselor were 
significantly associated (p=0.022). The association of year of graduation with attending a training 
program that addressed psychiatric genetics approached significance (p=0.051). Specialty and 
having ordered genetic testing for a psychiatric condition were also significantly associated 
(p=0.005), as were having attended a training program that addressed psychiatric genetics and 
disclosing secondary results related to psychiatric genetic counseling (p=0.046). (Table 7).  
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Table 7: Associations Between Demographic Factors and Psychiatric Genetics Practices 
  
Seen a patient 
whose 1° indication 
psychiatric 
condition 
Referred 
patient to 
psychiatric 
GC 
Disclosed 2° 
finding of 
psychiatric 
condition 
Tested for 
psychiatric 
condition 
Psychiatric 
genetics 
taught in 
program 
  P-Value P-Value P-Value P-Value P-Value 
Year of 
Graduation 0.18 0.022* 0.37 0.189 0.051 
Gender 0.718 0.214 1 1 0.596 
Region 0.296 0.218 0.197 0.093 0.248 
Specialty 0.36 0.068 0.274 0.005* 0.307 
Psychiatric 
genetics 
taught in 
program 0.53 0.717 0.046* 0.512 N/A 
*=p<0.05 
Assessing the significant associations, Table 8 indicates the percentage of individuals who 
have performed certain practices given their specialty, graduation year, and psychiatric genetic 
counseling training. Based on this data, the genetic counselors with the highest likelihood of 
having ordered genetic testing specifically for a psychiatric condition are those who work in Adult 
clinics (67%, n=2), those with the highest likelihood of having referred a patient to a psychiatric 
genetic counselor are those who graduated in the 1980s (50%, n=1), and those with the highest 
likelihood of having disclosed secondary findings related to psychiatric  conditions are those who 
don’t remember whether their training program addressed psychiatric genetics (38%, n=3/8). The 
true significance of these associations is suspect due to the low number of respondents in different 
demographic categories.  The chance of having been through a training program that addressed 
psychiatric illnesses steadily increased from zero if one graduated 1980-1989, 40% if one 
graduated 1990-1999, 56% if one graduated 2000-2009, and 73% if one graduated 2010-2019. 
(Figure 5) 
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Table 8: Psychiatric Genetics Practices Given Demographic Category 
 Has ordered testing n= 
Psychiatric 0.00% 0/2 
Cancer 5.00% 1/20 
Prenatal 0.00% 0/30 
Pediatric 19.05% 4/21 
Adult 66.67% 2/3 
Cardiology 50.00% 1/2 
General 33.33% 2/6 
Other 0.00% 0/6 
 
Has referred to a 
psychiatric GC n= 
Training 
program 
addressed 
psychiatric 
genetics n= 
1980-1989 50.00% ½ 0.00% 0/2 
1990-1999 0.00% 0/5 40.00% 2/5 
2000-2009 33.00% 3/9 55.56% 5/9 
2010-2019 6.20% 5/81 73.49% 61/83 
 Has disclosed secondary findings n= 
Received 
Training 9.00% 6/64 
No 22.00% 5/23 
Don’t 
Remember 38.00% 3/8 
 
 
Figure 5: Likelihood of Training Program Addressing Psychiatric Genetics by Graduation Decade 
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Fisher’s exact test was performed to evaluate the relationships between demographic 
factors and agreement with statements about confidence. The association between decade of 
graduation and agreement with the statement “I feel confident in my understanding of psychiatric 
genetics” was significant (p=0.004), as was the association between gender and agreement with 
that statement (p=0.047). No other associations with that phrase reached significance. None of the 
variables (gender, year of graduation, region, specialty, or having attended a training program that 
addressed psychiatric genetics) were significantly associated with agreement with the statement “I 
feel confident I could explain psychiatric genetics to a patient. (Table 9) 
Table 9: Association of Demographic Factors with Confidence 
  
I feel confident I could 
effectively explain 
psychiatric genetics to a 
patient 
I feel confident in my 
understanding of psychiatric 
genetics 
  P-Value P-Value 
Year of Graduation 0.368 0.004* 
Gender 0.41 0.047* 
Region 0.166 0.389 
Specialty 0.727 0.761 
Psychiatric genetics taught in 
training program 0.14 1 
*=p<0.05 
The significant relationships between decade of graduation and confidence, and between 
gender and confidence, were examined more closely. (Table 10) 70% of genetic counselors who 
graduated between 2010 and 2019 said they “Somewhat” or “Strongly Agree” that they felt 
confident in their understanding of psychiatric genetics. Women were more likely to agree that 
they felt confident in their understanding (77.50%) than men (25%). 
 
 
 55 
Table 10: Agreement with the statement “I feel confident in my understanding of psychiatric genetics” 
Year of Graduation Somewhat Agree/Strongly Agree n= 
1980-1989 50.00% 1/2 
1990-1999 60.00% 3/5 
2000-2009 62.50% 5/8 
2010-2019 70.00% 56/80 
Gender  n= 
Female 77.50% 62/80 
Male 25.00% 1/4 
Other 100.00% 1/1 
Prefer not to say 100.00% 1/1 
3.4 Discussion 
3.4.1  Practice 
The majority of participants in this study (68.69%) have never seen a patient for a primary 
indication of a psychiatric condition. Few have referred patients to psychiatric genetic counselors, 
disclosed secondary findings related to psychiatric conditions, or ordered genetic tests for 
psychiatric conditions. This finding corresponds with Hoop et al.’s survey of 45 psychiatrists that 
few healthcare professionals have referred patients to psychiatric genetic counseling.92 These low 
frequencies may reflect the dearth of psychiatric genetic counselors to be referred to and the 
absence of guidelines recommending genetic testing for psychiatric genetic counseling or how to 
interpret genetic test results related to psychiatric disorders. 41.9% of participants in this survey 
have ordered a genetic test for ASD, followed by dementia, ADD/ADHD, then depression, 
anxiety, and schizophrenia. The high proportion of respondents who have ordered tests for ASD 
may be due to the presence of more guidelines regarding genetic testing and results for ASDs and 
may also be influenced by parents requesting or pushing for genetic testing. The International 
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Society of Psychiatric Genetics has issued guidelines supporting the utility of microarrays in 
children with ASD or other neurodevelopmental disorders but has not come to a consensus on 
microarrays for adult-onset psychiatric disorders.69  
Most participants said they sometimes ask about personal or family histories of psychiatric 
conditions, and if those are present, sometimes discuss this with the patient. Respondents were 
more likely to discuss psychiatric personal or family histories if present than to ask about 
psychiatric personal or family histories. This may be due to genetic counselors tailoring sessions 
toward individual patients and what is relevant to their indication and history, rather than asking 
the same questions of every patient. In addition, counselors are more likely to ask about psychiatric 
conditions when getting personal history information than family history. It is possible this is due 
to perceptions that personal histories of psychiatric conditions are more relevant, which could 
indicate a lack of appreciation for the heritability of psychiatric disorders. This aligns with 
Moldovan et al.’s recent 2019 study, which found that across the world, most genetic counselors 
only discuss psychiatric genetics if it is brought up by the patient.94 This may be due to genetic 
counselors tailoring sessions toward individual patients and what is relevant to their indication and 
history, rather than asking the same questions of every patient. In addition, counselors are more 
likely to ask about psychiatric conditions when getting personal history information than family 
history. It is possible this is due to perceptions that personal histories of psychiatric conditions are 
more relevant, which could indicate a lack of appreciation for the heritability of psychiatric 
disorders.  
NSGC’s online course “Psychiatric Genetics across Genetic Counseling Practice Settings” 
advises on how to discuss psychiatry during a genetic counseling session and provides case 
examples for practice, as well as discussing testing options.129 Without concrete guidelines, 
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counselors are left to make their own assessments of psychiatric genetic counseling practices, such 
as when or if to order genetic testing, how and where to refer patients to psychiatric genetic 
counselors, and how to discuss risks. The genetic counselors in this study preferred discussing 
qualitative risk information (57.9%) over quantitative risk estimates (5.27%). Many of the 
respondents (29.47%) provide a combination of qualitative and quantitative risk, and they may 
tailor the risk discussion based on the patients’ questions and interest. Counselors may be more 
comfortable avoiding specific numbers because information about recurrence risks, polygenic risk 
scores, or genetic testing results is not yet concrete. 
The importance of relevance to the patient’s indication, as noted in responses to other 
survey questions, is a driving factor in decisions to ask about and discuss histories of psychiatric 
conditions, order genetic testing, and discuss psychiatric genetics with patients in general. This 
aligns with genetic counselors’ training to tailor sessions to individual patients. 
3.4.2  Confidence/Education 
The majority of respondents agreed that they felt confident in their understanding of 
psychiatric genetics and their ability to effectively explain it to patients. Recent graduates and 
women were the most likely to feel confident in their understanding, with 70% of graduates from 
2010-2019 agreeing they feel confident compared to approximately 50% of graduates from 1980-
1989. Although the association between gender and confidence was significant, the presence of 
only four male participants make have skewed the analysis. Higher confidence in recent graduates, 
who are also more likely to have received training in psychiatric genetics, aligns with the idea that 
more frequent instruction about psychiatric genetic counseling, practice, and access to patient 
resources had significant impacts on preparedness for psychiatric genetic counseling, as reported 
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by Low et al. in 2018.17 Overall, however, the high percentage of confident respondents contrasts 
with the low percentage of respondents who always discuss psychiatric genetics with their patients. 
This discrepancy may be due to the common tendency for individuals to overestimate their 
knowledge and confidence.145 
Most participants indicated their genetic counseling training programs provided 
information about psychiatric genetic counseling, usually by lecture, followed by conferences or 
seminars, clinical rotations, then extra-curricular or other methods. Active, involved experiences 
were shown to be particularly helpful by Low et al.;17 however, participants in this thesis survey 
did not indicate much hands-on practice or experience with psychiatric genetic counseling in their 
training programs, although three respondents did say they had patient simulations involving 
psychiatric genetics, and respondents who graduated 2010-2019 were the only cohort to report 
learning information about psychiatric genetics through extra-curricular activities and conferences 
or seminars, as well as several (n=9) through clinical rotations. Participants’ overall likelihood to 
have learned about psychiatric genetics increased over time, possibly because more genetic 
counseling programs have adjusted their curricula to reflect the increase in awareness and 
information about psychiatric genetics. 
3.4.2.1 Resources 
Respondents most frequently preferred journal articles, conferences or seminars, and 
online courses to stay up to date on general and psychiatric genetic information. These information 
sources may be preferred due to peer-review, production by a group of experts, and focus on factual 
information, rather than opinions. Email listservs and discussion with peers were not as popular 
for psychiatric genetics as general genetics. Perhaps this is due to fewer emails addressing 
psychiatric genetics and colleagues being unfamiliar with it. People were more likely to choose 
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online courses and podcasts, radio, and television for information on psychiatric genetics than for 
information on general genetics. This may be due to the recent growth of the field, as counselors 
may want to take online courses to supplement knowledge of psychiatric genetics that may not 
have been presented in their training programs or addressed since then. The increased preference 
for podcasts, radio, and television may be due to high media coverage of new advances in the field 
of psychiatric genetics.  
Some of the information respondents said they would find beneficial, such as case studies, 
associations between psychiatric conditions and other indications, and studies of the utility and 
efficacy of psychiatric genetic counseling, are available, while other information, like recurrence 
risks, polygenic risk scores, and pharmacogenetics is in the process of being researched and fine-
tuned to be useful for clinical practice. These selections of information reflect the 61.96% who 
said learning more about psychiatric genetics would increase their likelihood of discussing 
psychiatric genetics with patients and the 57.61% who selected information about evidence-based 
practice of psychiatric genetic counseling. Access to patient resources and ability to refer patients 
to psychiatric genetic counselors, more time available in session, practice to become more familiar 
with psychiatric genetic counseling, applicability to their patients, and knowledge about testing 
and screening options are important factors to consider if the field of psychiatric genetic counseling 
is to grow. Time constraints are a common barrier to adoption of new practices in healthcare across 
professions.17,128 
Physicians’ decisions about practices have been showed to be influenced by perceptions of 
the purpose of those practices and explicit interest from patients.127 Some of the genetic counselors 
of this study expressed similar concepts, by tailoring their discussions of psychiatric genetics and 
risk based on patients asking questions and expressing interest. Participants also expressed their 
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opinions that psychiatric genetic counseling may not be widely applicable or adopted until more 
clinically relevant information is available, such as new genetic tests, more concrete risk estimates, 
and pharmacogenetics information, which demonstrates that perceptions of management versus 
psychosocial uses of psychiatric genetic counseling may affect practice.128  
Relevance to the patients’ primary indication was the factor with the most influence on 
decisions to order genetic testing for psychiatric conditions, followed by current evidence for 
psychiatric genetic counseling. Confidence mainly had a moderate influence, as well as assessment 
of the patient’s comfort discussing mental health. The counselors’ level of comfort discussing 
mental health was ranked with the least influence on testing decisions. 
3.4.3  Study Limitations 
This study had a low response rate and small sample size, and therefore may not be fully 
representative of all members of NSGC. The differences in distribution patterns, particularly in 
large overrepresentation of recent graduates and the discrepancies in specialty distribution, may 
have impaired data analysis. It is possible that recent graduates are more inclined to participate in 
the student surveys sent through NSGC because they were recently in the position of sending 
surveys or otherwise gathering data for their own theses. Additionally, with the field of genetic 
counseling growing, training programs are adapting to accept more students, which in turn leads 
to more graduates. The over- and under-representations of specialties may be related to random 
sampling with a small sample size. 
Selection bias is another possibility with use of surveys; genetic counselors who are 
interested in psychiatric genetics may have been more likely to participate, and those with higher 
interest and awareness may be more likely to perform psychiatric genetic counseling practices like 
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referrals to psychiatric genetic counselors or ordering genetic tests, and may feel more confident 
in their knowledge due to their interest. Genetic counselors without familiarity or interest in 
psychiatric genetics could have been less likely to respond to the survey. This type of selection 
bias could have led to overestimation of confidence and frequency of psychiatric genetic 
counseling practices. Another limitation is the reliance on self-reported practices, with inaccurate 
memories skewing reports of frequency, or answering in ways they thought they should, which 
could also overestimate frequency of genetic counseling practices. 
3.4.4  Future Directions 
Comprehensive evaluation of how many patients with primary indications of psychiatric 
conditions are seen by genetic counselors in other specialties, how often patients present with a 
different indication but reveal personal or family histories of psychiatric conditions, how often 
testing incidentally identifies variants related to psychiatric conditions, and other measures of 
practice will be important to assess the current state of psychiatric genetic counseling. With a better 
idea of what is currently being practiced, further studies can then assess where problems lie and 
what interventions may be beneficial in optimizing patient care. Current data suggests that the way 
training programs teach about psychiatric genetic counseling, access to provider and patient 
resources, experience with individuals who have mental illness, access to journal articles, 
conferences, and online courses or webinars could be places to focus on for improved and 
increased sharing of psychiatric genetics information. Determining how best to make these 
improvements is an important future direction. For example, a conference lecture or panel designed 
to attract genetic counselors who are not already familiar with psychiatric genetic counseling may 
be an efficient way to introduce counselors to the resources that are currently available, as well as 
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invite discussion of what methods and practices other genetic counselors are currently using or 
find useful. Increasing the awareness of psychiatric genetic counseling is an important first step in 
growing the field. 
3.5 Conclusion 
Psychiatric genetic counseling can provide knowledge and understanding to patients and 
their families about their mental health issues and risks, as well as psychosocial support to relieve 
guilt, shame, blame, and fear surrounding psychiatric disorders. Stigma surrounding mental illness 
is often a barrier to individuals receiving care as well; because studies have shown exposure to 
mental illness is beneficial in reducing stigma, the trend of increasing training about psychiatric 
genetics in genetic counseling programs is promising. If more genetic counselors become 
comfortable with mental illness, patient care will improve, even beyond the field of psychiatric 
genetic counseling. While genetic counselors currently provide counseling on multiple genetic 
conditions that can include mental illness as one of multiple components, as more information 
about psychiatric genetics is discovered and translated into clinical use, such as polygenic risk 
scores and pharmacogenetic tests, genetic counselors will need to become familiar with asking 
questions about psychiatric history, discussing mental illness, interpreting pedigrees with 
psychiatric conditions, ordering and screening options, how and where to refer patients to 
psychiatrists, psychiatric genetic counselors, or other healthcare providers, and resources for 
patients. A goal of this study was to assess how often these practices are currently performed, and 
the results show that the majority of responding genetic counselors have not seen patients for 
psychiatric conditions, disclosed secondary findings related to psychiatric conditions, referred a 
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patient to a psychiatric genetic counselor, or ordered genetic testing for a psychiatric condition. 
Some genetic counselors are hesitant to perform psychiatric genetic counseling because of time 
limitations, unawareness of patient resources and referral options, not viewing psychiatric genetics 
as relevant to their clinic and patients, and not knowing how it could affect medical management. 
Because these practices are relatively new and many current genetic counselors may not 
have learned about psychiatric genetic counseling in their training programs, it is important that 
counselors have resources to learn more about psychiatric genetics and ways to incorporate it into 
their practices. This study revealed that genetic counselors would be most interested in journal 
articles, conferences or seminars, and online courses to receive this information. Additional studies 
of widespread psychiatric genetic counseling practices in nonpsychiatric genetics clinics could 
help develop useful resources about psychiatric genetic counseling for providers and patients. 
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4.0 Public Health Significance 
A core function of public health is assurance, and this study assesses current practices of 
genetic counselors in relation to psychiatric genetics and identifies gaps of care in order to ensure 
that the workforce is competent in psychiatric genetics. It also investigates what factors influence 
those practices, as well as genetic counselors’ confidence in knowledge. By determining how 
genetic counseling training programs, educational resources, and other factors affect counselors’ 
delivery of psychiatric genetic counseling services, interventions to standardize practices and 
improve knowledge can be developed. These interventions can improve provision of and access 
to care for individuals with mental illnesses and their families. 
The methods of resource development based on providers’ feedback and interest are 
applicable to many areas of health, and regular updates and resource development are key parts of 
maintaining knowledge for providers and health literacy for communities.146 Guidelines for 
practice and training programs involve policy development, another core function of public health. 
National organizations such as the National Society of Genetic Counselors, American Society of 
Human Genetics, American Board of Genetic Counseling, and others should continue publishing 
statements, recommendations, updates, and other communications to help providers remain up to 
date. The American Psychiatric Association encourages genetic counseling for individuals with 
bipolar disorder, and the International Society of Psychiatric Genetics has published 
recommendations for clinical use of genetic testing for psychiatric disorders.55,69 Ensuring that 
government policies and insurance companies reflect the current state of psychiatric genetics and 
psychiatric genetic counseling is also essential. Funding for research into clinical applications of 
psychiatric genetics, instituting specialized psychiatric genetic counseling clinics, and campaigns 
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to increase awareness of psychiatric genetic counseling services are vital tools to encourage 
adoption of practices and learning about psychiatric genetics will be necessary as psychiatric 
genetic counseling becomes more widespread and in demand. Evaluations of methods and 
outcomes of psychiatric genetic counseling in dedicated clinics as well as cancer, prenatal, 
pediatric, and other settings will provide assurance that counselors are using consistent, 
complementary data, patient resources, and strategies to optimize patient care. 
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Clinical research being conducted in an UPMC facility cannot begin until fiscal approval is received from 
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APPROVAL OF SUBMISSION (Exempt)
Date: June 7, 2019
IRB: STUDY19050028
PI: Kaitlin Sullivan
Title: Addressing psychiatric disorders in genetic counseling
The Institutional Review Board reviewed and approved the above referenced study.  The study may 
begin as outlined in the University of Pittsburgh approved application and documents. 
Approval Documentation
Review type: Initial Study
Approval Date: 6/7/2019
Exempt Category: (2)(ii) Tests, surveys, interviews, or observation (low risk), 
(2)(i) Tests, surveys, interviews, or observation (non-identifiable)
Approved 
Documents:
• Survey Exemption Worksheet, Category: IRB Protocol;
• Intro Script, Category: Recruitment Materials;
• Survey, Category: Data Collection;
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 Appendix B: Survey 
Psychiatric Disorders 
My name is Kaitlin Sullivan, and I am currently a genetic counseling student at the 
University of Pittsburgh.  I would like to invite you to participate in this research study that aims 
to evaluate how genetic counselors address psychiatric disorders and identify methods to 
increase genetic counselors’ familiarity with psychiatric genetics. Psychiatric genetics is the 
study of how genetics relate to the development of psychiatric disorders. To assess this 
information, we will be surveying genetic counselors (clinical and non-clinical) with a brief 
(approximately 10 minute) survey that includes questions about practices and opinions regarding 
psychiatric genetic counseling, as well as limited demographic information. It is anonymous, and 
your responses are not identifiable. The information that you give in the study will be handled 
confidentially. This survey is part of a Master’s in genetic counseling thesis project. 
Your participation in the study is completely voluntary. You may skip any question that you feel 
uncomfortable answering. You are free to exit the survey at any time. If you exit the survey 
before completing and submitting it, you may return to it at a later time.  
This survey is open to any current genetic counselor.  There are no anticipated risks in this study. 
There are no direct benefits to you for participating in this research study.  The study may help 
us develop resources in the future to enhance genetic counselors’ knowledge of and comfort with 
psychiatric genetic counseling.  This study was approved as an exempt study by the University of 
Pittsburgh IRB, Study #19050028. 
Thank you for taking the time to consider this study. 
        If you have questions, please contact: 
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 Kaitlin Sullivan 
 Kms335@pitt.edu 
  
 Department of Human Genetics 
 University of Pittsburgh 
 130 DeSoto St 
 Pittsburgh, PA 15261 
 
In what year did you graduate from a genetic counseling graduate program? 
o2019  
o2010-2018  
o2000-2009  
o1990-1999  
o1980-1989  
o1971-1979  
 
 
What is your gender? 
oMale  
oFemale  
oOther  
oPrefer not to answer  
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In what region are you located? 
oRegion I (CT, MA, ME, NH, RI, VT, Canadian Maritime Provinces)  
oRegion II (DC, DE, MD, NJ, NY, PA, VA, WV, Quebec, Puerto Rico, Virgin Islands)  
oRegion III (AL, FL, GA, KY, MS, NC, SC, TN)  
oRegion IV (AR, IA, IL, IN, KS, MI, MN, MO, ND, NE, OH, OK, SD, WI, Ontario)  
oRegion V (AZ, CO, MT, NM, TX, UT, WY, Alberta, Manitoba, Saskatchewan)  
oRegion VI (AK, CA, HI, NV, OR, WA, British Columbia)  
 
 
What is your primary area of specialty? 
oPsychiatric  
oCancer  
oPrenatal  
oPediatric  
oPreconception  
oAdult  
oCardiology  
oSpecialty disease (please specify): ____________________________________________ 
oGeneral  
oLaboratory  
oEducation  
oOther (please specify): ________________________________________________ 
oN/A – I am not currently practicing as a genetic counselor  
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Skip To: Q14 If What is your primary area of specialty? = N/A – I am not currently practicing as 
a genetic counselor 
Skip To: Q14 If What is your primary area of specialty? = Laboratory 
Skip To: Q6 If What is your primary area of specialty? = Psychiatric 
Have you ever seen a patient whose primary indication was a psychiatric condition? 
oYes  
oNo  
 
 
When gathering personal history information, how often do you ask about psychiatric 
conditions? 
oAlways  
oSometimes  
oNever  
 
 
When gathering family history information, how often do you ask about psychiatric 
conditions? 
oAlways  
oSometimes  
oNever  
 
 
If a patient has a personal or family history of psychiatric conditions, how often do you 
discuss this with the patient? 
oAlways  
oSometimes  
oNever  
 
Skip To: Q10 If If a patient has a personal or family history of psychiatric conditions, how often 
do you discuss... = Never 
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When discussing psychiatric disorders, how do you present risk information? 
oI provide quantitative risk/recurrence numbers  
oI provide qualitative risk information  
oI provide both quantitative and qualitative risk information  
oI provide other information (please specify): ____________________________________ 
 
 
Have you ever referred a patient to a psychiatric genetic counselor? 
oYes  
oNo  
 
 
Have you ever disclosed secondary findings related to a psychiatric condition when 
returning results to a patient? 
oYes  
oNo  
 
 
Have you ever ordered genetic testing specifically for a psychiatric condition? 
oYes  
oNo  
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For which conditions have you ordered genetic testing? (Select all that apply) 
▢Depression  
▢Anxiety  
▢ADD/ADHD  
▢Schizophrenia/schizoaffective disorder  
▢Psychosis  
▢Bipolar disorder  
▢Personality disorder  
▢Alcohol/substance abuse  
▢Eating disorder  
▢Autism spectrum disorder  
▢Dementia  
▢Other: ________________________________________________ 
▢None of the above  
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To what degree do the following factors play a role in your decision whether or not to 
discuss psychiatric conditions in session?  
 No Influence Low Degree Moderate Degree High Degree 
Relevance 
to the patient's 
primary indication  o o o o 
Confidence 
in my knowledge 
of psychiatric 
genetics  
o o o o 
Amount of 
current evidence 
for psychiatric 
genetic counseling  
o o o o 
Level of 
comfort talking 
about mental 
health  
o o o o 
Assessment 
of the patient's 
level of comfort 
talking about 
mental health  
o o o o 
Other 
(please specify):  o o o o 
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To what level do you agree with the following statements: 
 Strongly Disagree 
Somewhat 
Disagree 
Neither agree 
nor disagree 
Somewhat 
agree 
Strongly 
Agree 
I feel 
confident in my 
understanding of 
psychiatric 
genetics  
o o o o o 
I feel 
confident I could 
effectively explain 
the genetics of 
psychiatric 
conditions to a 
patient  
o o o o o 
 
Did your genetic counseling training program’s curriculum include information about 
genetic counseling for psychiatric conditions? 
oYes  
oNo  
oI don't remember  
 
Skip To: Q17 If Did your genetic counseling training program’s curriculum include information 
about genetic couns... = No 
Skip To: Q17 If Did your genetic counseling training program’s curriculum include information 
about genetic couns... = I don't remember 
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How was information about genetic counseling for psychiatric conditions provided? 
(Select all) 
▢Classes  
▢Clinical rotations  
▢Extra-curricular activities  
▢Conferences or seminars  
▢Other (please specify): ______________________________________________ 
 
What resources do you use to stay current on information about genetic counseling in 
general? (Select all that apply) 
▢Journal articles  
▢Conferences or seminars  
▢Blogs or social media (Facebook, Twitter, Instagram)  
▢Podcasts, radio, or television  
▢Email listservs from professional organizations  
▢Discussion with colleagues  
▢Online courses or webinars  
▢Other (please specify): ______________________________________________ 
▢None of the above  
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What types of resources would you find most helpful to learn about psychiatric genetics? 
(Select all that apply) 
▢Journal articles  
▢Conferences or seminars  
▢Blogs or social media (Facebook, Twitter, Instagram)  
▢Podcasts, radio, or television  
▢Email listservs from professional organizations  
▢Discussion with colleagues  
▢Online courses or webinars  
▢Fact sheets or reference lists  
▢Other (please specify): ______________________________________________ 
▢None of the above  
 
What types of information about psychiatric genetics would you find most useful in your 
practice? (Select all that apply) 
▢Recurrence risks  
▢Pharmacogenetics  
▢Polygenic risk scores  
▢Case studies  
▢Associations between psychiatric conditions and other patient indications (i.e. 
genetic syndromes, neurodevelopmental disorders)  
▢Studies of psychiatric genetic counseling utility and efficacy  
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▢Other: ________________________________________________ 
 
Are you aware of NSGC's online course "Psychiatric Genetics across Genetic Counseling 
Practice Settings?" 
oI have taken this course  
oI am aware of this course, but have not taken it  
oNo  
 
In the last year, have you attended a lecture, panel, or other speaking event (at a conference 
or otherwise) regarding psychiatric genetics? 
oYes  
oNo  
 
What factors would increase your likelihood discussing psychiatric genetics with patients? 
(Select all that apply) 
▢Learning more about psychiatric genetics  
▢Having access to more patient resources  
▢More information about evidence-based practice of psychiatric genetic 
counseling  
▢Other: ________________________________________________ 
▢None of the above  
 
Optional: How do you see psychiatric genetic counseling being incorporated into genetic 
counseling sessions in the future? 
________________________________________________________________ 
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